Page 1

Missouri TECH EXPO


Hosted by the OFFICE OF TECHNOLOGY MANAGEMENT & INDUSTRY RELATIONS at the University of Missouri



Schedule of Events


Welcome from the MU Interim Vice Chancellor for Research, Graduate Studies and Economic Development Mark McIntosh


Welcome from the Director of the MU Office of Technology Management and Industry Relations Chris Fender


Next-Big-Thing Speakers




“Where Are They Now” Success Stories


Campus Technology Transfer Offices


U.S. Patents Issued to the University of Missouri System FY2016 (July 1, 2015 – June 30, 2016)


Engineering Abstracts


Health Sciences Abstracts


Life Sciences Abstracts


Software Abstracts



Published by the MU Office of Technology Management and Industry Relations. Copyright© 2016, The Curators of the University of Missouri. All rights reserved. An equal opportunity, affirmative action institution. 3


7:30 - 8:00 a.m.

Registration, Sponsor & Display Setup Monsanto Auditorium lobby & Mezzanine (located up the stairs from the lobby)

8:00 - 8:30 a.m.

Continental Breakfast, Mezzanine

8:30 - 8:45 a.m.

Welcome & Introductions, Monsanto Auditorium • Mark McIntosh, Interim Vice Chancellor for Research, Graduate Studies & Economic Development • Hank Foley, Interim MU Chancellor

8:45 – 9:45 a.m.

Next-Big-Thing Presentations, Monsanto Auditorium • George Chronis, CEO & Chief Technology Officer, Foresite Healthcare • Joe Boswell, CEO & Co-Founder, ThermAvant Technologies

9:45-10:45 a.m.

Life Sciences Tech Pitches, Monsanto Auditorium Investment & licensing-stage technologies: • Chris Lorson — Spinal muscular atrophy therapeutic • Kevin Keegan — Wireless lameness detection • Gary Yao — High resolution medical imaging • Teresa Lever — Swallowing disorder analysis device • Kevin Gillis — Exocytronics, exocytosis measurement

10:45-11:00 a.m.

Networking & Refreshments, Mezzanine

11:00 a.m. – 12:00 p.m.

Health Sciences Tech Pitches, Monsanto Auditorium Investment & licensing-stage technologies: • Sheila Grant — ACL grafts with nano-gold conjugates • Kattesh Katti — Nano-Ayurvedic medicine to treat cancer • Chuck Caldwell — Peptide staining to detect PD-L1 in tumors • Michael Puricelli — Surgical punch for ear surgery

12:00 - 1:30 p.m.

Lunch, McQuinn Atrium Chris Fender, Director, MU Office of Technology Management & Industry Relations Mike Middleton, Interim President, University of Missouri System

1:30 - 2:30 p.m.

Engineering Tech Pitches, Monsanto Auditorium Investment & licensing-stage technologies: • Bret Ulery — POSH inhibitors, a novel cancer therapeutic • Mahmoud Almasri — ALMA Microsystems, biosensors for pathogen detection • William Jacoby — Simple carbon capture • Peter Motavalli — Crop chemicals & fertilizer software tools

2:30 - 3:00 p.m.

Networking & Refreshments, Mezzanine

3:00 – 4:00 p.m.

Software Tech Pitches, Monsanto Auditorium Investment & licensing-stage technologies:  Prasad Calyam — Panacea’s Cloud, tool for emergencies  Dmitriy Shin — Medical diagnostics skills  Kannappan Palaniappan — Moving object recognition  Hadi Ali Akbarpour — Robust aerial imagery Closing Remarks Chris Fender, Director, MU Office of Technology Management & Industry Relations






U’s Office of Research, Graduate Studies and Economic Development is pleased to welcome you to the 2016 Missouri Technology Expo, an event showcasing the crucial role our state’s top research institutions play in advancing Missouri’s innovation economy. Our office works to ensure that MU’s research, instruction, service and economic-development missions help promote discovery, creativity, and innovation among our faculty, staff and students. Doing this involves moving forward on what interim MU Chancellor Hank Foley has described as an important change in the way university researchers approach our work. We must build relationships among faculty at each of our four UM System campuses, construct closer ties to businesses that can leverage our discoveries, support campus-based entrepreneurs and next-generation enterprises, and open up restrictive intellectual property policies that might impede their progress.

As we have argued in the past, maximizing the potential of these efforts will require new thinking in five key areas: encouraging faculty in the entire University of Missouri System — our campuses, research parks, business incubators, agricultural research stations, health centers and affiliates, and others — to join together in a “culture of collaboration” that will allow for a true synergy across the state; “growing our own” entrepreneurs and innovators by building an entrepreneurial ecosystem that allows translational start-ups to take root and thrive; being smarter about intellectual property by loosening IP ownership policies; extending the university’s definition of success to include invention, innovation and entrepreneurship; and, finally, looking beyond our institutional biases and accept that we have much to learn from the achievements of others. Fortunately, there is ample evidence that this new approach is already paying dividends. The university’s number of active options and licenses — an indicator of the rate at which MU research findings are moving into the marketplace — was at an all-time high during the previous fiscal year, and licensing income from these projects has continued to increase, buoyed by a major licensing settlement. This new licensing income has provided important new opportunities to invest millions of dollars into the aging technology infrastructure across the many MU disciplines. In addition, our research enterprise as a whole remains robust. During the previous fiscal year, internal research investments and extramural funding agency support generated more than $246 million in spending by faculty scientists and scholars at MU, a healthy four-percent increase over the previous fiscal year. Newly awarded federal dollars, most coming in the form of highly competitive grants from agencies such as the National Institutes of Health and the National Science Foundation, saw significant increases for both sponsored research and instruction and public service. And though federal research expenditures were slightly lower in FY2015 than the previous year, federal research awards showed a healthy 4.8 percent increase. Since becoming interim vice chancellor, I have spent a great deal of time working to ensure that we continue to move forward. Among my priorities for ensuring continued advancement is more fully integrating our graduate studies and economic development missions into the research enterprise. Our graduate students, for example, provide the engine that drives our research productivity and offer fresh and creative perspectives as they assist faculty with teaching and research. I believe, and hope you’ll agree, that today, more than ever, we are well-positioned to maximize MU’s already considerable value, both intellectually and economically, to the citizens of Missouri and the nation. I hope you will visit us at to learn more about our vision for the future of MU research, and to share with us your own ideas about how the university and its partners can contribute to a smarter, more prosperous Missouri.

Mark McIntosh MU Interim Vice Chancellor for Research, Graduate Studies and Economic Development 5




elcome to the 2016 Missouri Technology Expo. Once again, the Expo represents an opportunity to showcase technologies from Missouri’s top

research institutions that are available for licensing. It is our pleasure to provide a forum for researchers, entrepreneurs, investors and accomplished business professionals to interact, laying the foundation for exciting and lucrative technology commercialization ventures. The 2016 Missouri Tech Expo begins with presentations by two companies poised to become The Next Big Thing! Foresite Healthcare Foresite has a spectrum of innovative, constant-monitoring solutions across the continuum of care designed to enhance safety, reduce risk and detect illnesses earlier than ever thought possible. Foresite helps hospitals, rehabilitation centers, assisted-living facilities and nursing homes increase the quality of care and safety they provide while decreasing the cost of care.

Without ever touching the individual, Foresite continuously monitors heart and respiratory rates, bed restlessness, gait, falls, motion and activity—all in a privacy-protecting manner. Monitoring vital signs and movements enables early detection of strokes, congestive heart failure, upper respiratory infections such as pneumonia, urinary tract infections and other illnesses. Thermavant Technologies ThermAvant designs, develops and delivers custom thermal solutions to improve size, weight, performance and/or costs of advanced energy and technology platforms. The leading provider of Oscillating Heat Pipe products, ThermAvant also offers custom cold plates, ejector refrigerators and design and engineering services. The day continues with “elevator pitches” for a wide range of technologies presented according to their industry sector. Pitches include early-stage technologies, allowing presenters to provide in-depth information on the technology, as well as later-stage technologies seeking funding where the focus will be more concisely on the unique business opportunity for each technology. The drive and determination required to succeed as an entrepreneur is constant, no matter the industry. Our goal is to provide a conduit between potential investors in high-tech/high-growth ventures, entrepreneurs and ground-breaking innovations — the raw material of these ventures. We are grateful to Thompson Coburn for their continued support and sponsorship of the Tech Expo and University of Missouri inventors. Once again, we are pleased you could join us and our efforts to strengthen Missouri’s economy by facilitating the transfer of technologies into the marketplace where the fruits of research can truly impact our society.

Chris Fender Director, Office of Technology Management and Industry Relations 6



CEO & CHIEF TECHNOLOGY OFFICER, FORESITE HEALTHCARE George Chronis is CEO of Foresite Healthcare, a company that commercializes technology to improve quality of life by generating early illness alerts. He was instrumental in the development of Foresite Patientcare™, Foresite Eldercare™ and Foresite Health at Home™. Chronis earned two degrees at MU. He received his doctoral degree in robotics and artificial intelligence in 2007 and his master’s degree in computer science in 1998. His work and publications are in computational intelligence and include autonomous mobile robot navigation, spatial relations, linguistic spatial cognition, programming by demonstration, fuzzy logic and evolutionary computation. Before joining the Foresite Healthcare team, Chronis founded CyberSense, a software solutions and development company that has undertaken projects with more than 100 organizations worldwide in both higher education and commercial sectors. Projects developed and managed span a wide variety of demanding, large-scale data and computation-intensive applications.

JOE BOSWELL CEO & CO-FOUNDER, THERMAVANT TECHNOLOGIES Joe Boswell is an experienced engineer and entrepreneur who leads the financial and business development efforts at ThermAvant. Boswell also contributes to technology, product and process development on ThermAvant’s leadership and engineering teams. Before joining ThermAvant, Boswell was the founding chief financial officer of InsideTrack Inc. He helped build the company from five employees to more than 160 and raised the company’s first two rounds of institutional financing. He also was a mergers and acquisitions banker at J.P. Morgan and has written or cowritten six journal publications related to oscillating heat pipes. Boswell has been the principal Investigator on nine research and development projects since 2009 and is the named inventor on four of ThermAvant’s patents (granted or pending). Boswell graduated from the University of Pennsylvania’s Management & Technology program with degrees from the Wharton School of Business and the School of Engineering and Applied Sciences.

EXPO SPONSOR Thompson Coburn LLP is a full-service law firm with offices in Chicago, Los Angeles, St. Louis, Southern Illinois and Washington, D.C. With over 370 attorneys — more than 100 of whom have been selected for inclusion in The Best Lawyers in America® (Copyright 2013 by Woodward/White, Inc., of Aiken, S.C.) — the firm has experience in more than 50 areas of law. Thompson Coburn has tried the longest jury trial and one of the largest civil suits in American history and closed deals coast-to-coast and around the globe. The lawyers in the firm’s Chicago, Los Angeles, St. Louis, Southern Illinois and Washington, D.C. offices serve clients in a full spectrum of business sectors, including a number of universities and life


WHERE ARE THEY NOW? ORGANOVO — MU Professor Gabor Forgacs and his research team developed 3-D bioprinting. Their technology, licensed by Organovo, uses “bioink” made from cells to build living tissues with broad applications in toxicology, preclinical drug testing and regenerative medicine. The company’s 3-D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, Organovo’s technology has been featured in The Wall Street Journal, TIME magazine, The Economist, Forbes and other media. Organovo is listed on the NASDAQ Stock Market under the symbol “ONVO.” In September 2016, the company added Human Kidney Tissue to their ExViveTM Human Liver Tissue product and service portfolio (


ETERNOGEN — MU Biodesign and Innovation Program fellows and Professor Sheila Grant and her research team discovered that gold nanoparticles extend the life and stability of collagen. EternoGen’s mission is to provide superior collagen-based products for minimally invasive surgical applications. The company, which has offices in Columbia and St. Louis in Missouri and an office in Stockholm, Sweden, announced its plans to enter the commercialization phase in 2012. To date, Eternogen has secured $8.5 million in funding for European commercialization of Rapid Polymerizing Collagen, the first in a rich pipeline of new treatment products for bio-dermal restoration (


ELEMENTAL ENZYMES — Elemental Enzymes is a life sciences company focused on generating cutting-edge solutions, ranging from organic to biotechnological advances in a variety of fields. In 2008, MU postdoctoral investigator Brian Thompson and George Stewart, a professor in the MU Department of Veterinary Pathobiology, discovered a bacterial production system capable of producing enhanced enzymes, proteins and peptides. This discovery is the foundation of Elemental Enzymes technology, which allows enzymes to operate under higher temperatures and last longer in harsh environments or industrial processes. In 2014, the company, which maintains research labs in Columbia and St. Louis, Mo., announced a cross-licensing agreement with Bayer CropScience to further its research on crop productivity (


BEYOND MEAT — MU Professor Fu-Hung Hsieh and his team developed a soybased meat substitute that replicates the taste, texture and appearance of chicken. This technology was licensed to Savage River Farms and is commercialized under the brand “Beyond Meat.” Products, manufactured in Columbia, Mo., are available at 10,000 stores nationwide. The company has received significant media attention, including coverage on NBC Today, CBS This Morning, MSNBC and in The New York Times. Beyond Meat recently launched The Beyond Burger™, the world’s first plantbased burger that looks, cooks and tastes like a fresh beef burger. And elite athletes are partnering with the company to promote the benefits of plant-based protein (


MEDSOCKET — MedSocket licensed health information technology invented by former MU physician Karl Kochendorfer, who sought user-friendly solutions to the growing amount and complexity of electronic medical records. The company was created in 2012 to improve the efficiency and quality of patient care through advanced clinical decision support, information-retrieval and knowledge-management technologies. MedSocket’s products give practicing clinicians access to evidencebased information with unprecedented speed and simplicity. The technologies, which have been successfully piloted at MU Health Care, University of Illinois Health System and the Cleveland Clinic, show potential to improve health care decisions, increase efficiency, decrease health care costs and improve patient care ( 8



COMPANIES DEVELOP UNIV ERSIT Y TECH NOLGY EYEVERIFY — EyeVerify Inc. is a Kansas City company that licensed biometric technology developed by Reza Derakhshani, an associate professor in UMKC’s School of Computing and Engineering. The company created Eyeprint IDTM, a verification technology that makes a person’s eye the only password needed to secure smart phones and mobile devices. An Eyeprint contains the visible veins and other unique micro features in and around the eye that are highly complex and unique to every individual. In September 2016, Ant Financial Services Group, a leading online and mobile financial services provider and operator of Alipay, acquired EyeVerify, which has 17 U.S. patents and 15 additional patents pending (


IMPEDX DIAGNOSTICS — ImpeDx licensed a technology for rapid bacteria detection developed by MU Professor Shramik Sengupta and his research team. The company’s aim is to reduce the mortality rate of patients with sepsis infections. ImpeDx’s technology compresses blood culture results from days to hours, allowing clinicians to administer targeted therapeutic treatments sooner, saving lives and decreasing health care costs. The company has secured more than $3 million through the National Institutes of Health Small Business Innovation Research program and $500,000 from private investors. In addition to hiring two recent MU graduates, ImpeDx is conducting two clinical trials at University Hospital in Columbia, Mo. (


MODERN MEADOW — MU Professor Gabor Forgacs and his research team developed a technology for use in culturing meat without the need for animal slaughter. Their technology is licensed to Modern Meadow, a New York-based company that is using the latest advances in biotechnology, materials science and engineering to produce biofabricated leather. In June 2016, the company announced $40 million in second-round financing for biofabricated leather, bringing the total raised to $53.5 million. This investor support will enable Modern Meadow to transition from research and development to manufacturing (


ADSORBED NATURAL GAS PRODUCTS — MU researchers found that corncob carbon briquettes had a large amount of surface area, capable of storing cleanerburning natural gas at much lower pressures and in greater quantity than current technologies allow. ANGP, a company that develops and manufactures adsorbed natural gas storage products to fuel motor vehicles, licensed the technology as a blocking strategy while working with Mead Westvaco Specialty Chemicals. Mead, renamed Ingevity Corp., had pioneered the technology using hardwood as a source in the late 1980s. Although it stores less than the MU carbon, Ingevity’s process produces carbon more suited to internal combustion engine fueling. ANGP announced in May 2016 that it successfully installed the industry’s first ANSI NGV2 certified adsorbed natural gas active storage system in a Ford F-150 pickup truck and was honored with Frost & Sullivan’s 2016 New Product Innovation Award.


NANOVA — Hao Li and Qingsong Yu, MU mechanical and aerospace engineering faculty, first applied nanofiber composite technology in the fields of dentistry and orthopedics to develop products with improved strength and biological properties. Their technology, licensed by Nanova Biomaterials Inc., has received a venture capital investment of more than $7 million. Nanova also is developing a multiple function dental plasma brush for more durable restoration, a coronary stent with reduced restenosis and thrombosis and antimicrobial compounds with a novel anti-virulence mechanism that disarms bacteria instead of killing them. Notably, the antimicrobial compounds ( impose less selective pressure for the bacteria and may not lead to drug resistance, a common problem for conventional antibiotics (



We think your idea could use some black and gold

We believe in the power of ideas to change the world. We connect community leaders, entrepreneurs and business owners with exceptional faculty, staff, researchers and students at the University of Missouri. Contact Associate Vice Chancellor & Vice Provost Steve Wyatt or 573-882-3087

The Business of Science MU’s Office of Technology Management and Industry Relations (OTMIR) works to identify, assess, protect and market commercially viable intellectual property developed at the University of Missouri, including these specific functions: • Filing for intellectual property protection with U.S. and foreign patent and trademark offices; • Negotiating all intellectual property agreements; • Facilitating industry relations by negotiation and execution of material transfer and non-disclosure agreements; • Assisting with negotiation of intellectual property provisions in industry-sponsored research contracts. We strive to facilitate pathways for MU technology to create impact in our society, build and enhance relationships with industry and stimulate regional economic growth. In FY2016, 104 disclosures were received, 42 licenses and options were executed and more than $14.9 million in licensing revenue was received. OTMIR filed 77 U.S. Patent applications and had 24 U.S.-issued patents in FY2016.

In addition, 173 non-disclosure agreements and 370 material transfer agreements were executed. Our experienced central administrative staff receives invention disclosures, works with inventors to collect documentation, manages financial records and provides general support to the OTMIR team. Intellectual Property Licensing Units (IPLUs) are strategically embedded within the colleges and research centers that generate the majority of invention disclosures at MU. They are staffed by scientific, business and legal experts who work with MU researchers to analyze inventions for novelty, attainability of intellectual property protection and marketability. Our licensing professionals have industrial and academic expertise in agronomy, biological and chemical engineering, reproductive physiology, cell and molecular biology, as well as many aspects of pharmaceutical research. The OTMIR team provides the optimal vehicle for successful technology commercialization for MU’s diverse and productive research programs.

Mizzou’s Tech-Transfer Team Chris Fender, MS

Amos Angelovici, M.Sc.

Wayne McDaniel, PhD

Entrepreneur in Residence 109 MU Life Science Business Incubator at Monsanto Place 573-882-9829

Associate Director Engineering/Physical Sciences IPLU W1038 Lafferre Hall 573-884-3302

Harriet Francis, MS, JD

Charlie Hanford, JD

Jeffrey Erickson, JD

Laura Roloff, MA

Brett Maland, MBA, JD

Jing Sun, MS

Sam Bish, PhD

Director 124D MU Life Science Business Incubator at Monsanto Place 573-884-8296

Carolyn Dawson

Executive Assistant 124A MU Life Science Business Incubator at Monsanto Place 573-884-2802

Intellectual Property Manager 124C MU Life Science Business Incubator at Monsanto Place 573-882-4286

Fiscal Manager 124F MU Life Science Business Incubator at Monsanto Place 573-882-0229

John Rinck

Office Support Associate 124I MU Life Science Business Incubator at Monsanto Place 573-882-0213

Senior Contracting Officer 124H MU Life Science Business Incubator at Monsanto Place 573-884-0374

Strategic Communications Manager 124B MU Life Science Business Incubator at Monsanto Place 573-884-0023

Sr. Licensing Associate Agriculture/Life Sciences IPLU 440B Bond Life Sciences Center 573.882.5016

Nancy Parker, PhD

Licensing Associate Agriculture/Life Sciences IPLU 440A Bond Life Sciences Center 573.884.3553

Licensing Assistant Health Sciences IPLU NW504 Health Sciences Center 573-882-0477

Senior Licensing Associate Software/Copyright IPLU W1039 Lafferre Hall 573-882-1046 Administrative Office Agriculture & Life Sciences IPLU Engineering & Physical Sciences IPLU Health Sciences IPLU Software and Copyright IPLU


MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY OFFICE OF TECHNOLOGY TRANSFER AND ECONOMIC DEVELOPMENT The Office of Technology Transfer and Economic Development (TTED) serves as the focal point for technology commercialization, entrepreneurship and economic development at Missouri S&T. Its mission is to grow Missouri’s economy by advancing technology commercialization, encouraging entrepreneurship and promoting business opportunities. Located in the Technology Development Center at Innovation Park, TTED manages a variety of programs and initiatives including various services for students, faculty and staff.

TTED hosts a Small Business & Technology Development Center (SBTDC) as part of the Missouri SBTDC statewide network. SBTDCs are partnerships, primarily between the government and colleges and universities, administered by the United States Small Business Administration. They aim to provide counseling and educational services for small business owners and aspiring entrepreneurs. The Student Business Incubator and the VentureLab are programs launched by TTED to support student and community entrepreneurs. The programs operate out of a co-working space in the Technology Development Center at Innovation Park. They provide participants with business counseling and access to work space, conference rooms, and other vital resources to help them develop and successfully launch their businesses ventures. Information about these programs can be found at and We are in the third year of our Entrepreneurial COOP and Internship, providing students the opportunity to work full time on their emerging business ideas. One of the primary functions for TTED is managing Missouri S&T’s Intellectual Property portfolio. This includes evaluating the patentability and commercial potential of inventions developed by Missouri S&T faculty researchers, securing intellectual property rights for promising innovations, and commercializing Missouri S&T technologies by licensing them to established businesses and university spin-off companies. TTED plays an important role in a variety of other important initiatives, including the development of Innovation Park (Missouri S&T’s 50-acre research park) and managing the Technology Development Center at Innovation Park. The center is home to 17 companies ranging from faculty and student start-ups to local offices of fortune 500 companies, such as Garmin Inc. and The Boeing Company. The center is also home to “Tech-44 – The Ideas Highway,” a regional economic development initiative. See for more details. For more information, please contact Keith Strassner, director, Technology Transfer and Economic Development, 573-341-6725, or visit us online at



UNIVERSITY OF MISSOURI-KANSAS CITY OFFICE OF TECHNOLOGY COMMERCIALIZATION The UMKC Office of Technology Commercialization, within Research and Economic Development, helps UMKC faculty and researchers transfer university inventions to the marketplace and turn their innovative ideas into products, technologies and services that can benefit society. Missouri universities are strong contributors to the creation of new technologies, companies, industries and jobs. Tech transfer professionals are a highly specialized group of university employees who manage the complex process of protecting discoveries that may become new products, technologies or services. We do this by securing patents, so that our discoveries can be licensed and further developed, or produced by existing companies, or startups. EyeVerify is just one example of a successful license agreement with UMKC. EyeVerify has commercialized the biometric research of Professor Reza Derakhshani of the School of Computing and Engineering. A winner of numerous small business and entrepreneurial awards, EyeVerify was recently acquired by Ant Financial Services Group. The UMKC Office of Technology Transfer works closely with inventors to receive, review and promote new discoveries, with 22 invention disclosures submitted in FY2016. For more information please see UMKC technologies available for license can be reviewed at For more information, please contact Eric Anderson, director, Office of Technology Commercialization, 816-235-5091 or

UNIVERSITY OF MISSOURI - ST. LOUIS TECHNOLOGY TRANSFER OFFICE The University of Missouri-St. Louis Technology Transfer Office (TTO), housed within the Office of Research Administration, promotes and facilitates the transfer of UMSL innovations to industry for the benefit of the university and public well being. The TTO works to grow the economy of both the St. Louis region and the state of Missouri through commercializing technologies, catalyzing collaborations among researchers and between faculty and industry, and fostering entrepreneurship on and off campus.  

For more information, please contact Tamara Wilgers, director, Technology Commercialization and Economic Development, at 314-516-6884 or



HIGH FREQUENCY ANALYSIS OF A DEVICE UNDER TEST — Reza Zoughi, Mohamed Ahmed AbouKhousa and Sergiy Kharkivskiy (S&T)


APPARATUS AND METHOD FOR DETERMINATION OF ONE OR MORE FREE NEUTRON CHARACTERISTICS — Steven L. Bellinger, Anthony N. Caruso, Brian Cooper, William L. Dunn, Ryan G. Fronk, Douglas S. McGregor, William H. Miller, Eliot R. Myers, Thomas M. Oakes, Philip B. Ugorowski, John K. Shultis, Timothy J. Sobering and Cory B. Hoshor (UMKC)


MULTIPLE PHASE FLOW SYSTEM FOR DETECTING AND ISOLATING SUBSTANCES — Christine Mary O’Brien, Sagar K. Gupta, John Andrew Viator, Shramik Sengupta, Jeff Mosley and Kyle Rood (MU)


APPARATUS AND METHOD FOR STERNAL CLOSURE — Wayne C. McDaniel, Joseph T. Walls and Janet L. Rettenmaier (MU)


MULTIFUNCTIONAL POROUS ARAMIDS (AEROGELS) AND FABRICATION THEREOF — Nicholas Leventis, Chariklia Sotiriou-Leventis and Malik Adnan Saeed (S&T)






DEEP LEVEL TRANSIENT SPECTROMETER — Daniel E. Montenegro, Jason B. Rothenberger, Mark A. Prelas, Robert V. Tompson and Annie Tipton (MU)




SERS SUBSTRATES — Hao Li, Mengshi Lin and Qingsong Yu (MU)






GUANIDINYL-SUBSTITUTED POLYAMIDES USEFUL FOR TREATING HUMAN PAPILLOMA VIRUS — James Bashkin, Terri G. Edwards, Christopher Fisher, George D. Harris and Kevin J. Koeller (UMSL)


REUSABLE PCR AMPLIFICATION SYSTEM AND METHOD — Venumadhav Korampally, Shubhra Gangopadhyay, Keshab Gangopadhyay, Sheila A. Grant, Steven B. Kleiboeker, Shantanu Bhattacharya and Yuanfang Gao (MU)


BIOMATERIAL COMPOSITIONS — Kathleen Kilway, Linda Bonewald and Thomas Schuman (UMKC)




CLUSTER BORON COMPOUNDS AND USES THEREOF — George R. Kracke, Yulia Sevryugina and Marion Frederick Hawthorne (MU)


GOLD-COATED LANTHANIDE NANOPARTICLES — John David Robertson, Mark F. McLaughlin and Paul H. Pevsner (MU)


FREE-HAND SCANNING AND IMAGING — Joseph T. Case, Mohammad Tayeb Ghasr, and Reza Zoughi (S&T)

KCNQ CHANNELS AS THERAPEUTIC TARGETS — Jianmin Cui, Ira S. Cohen and Xiaoqin Zou (MU)




EGCG CONJUGATED GOLD NANOCEUTICAL AND METHOD FOR MAKING SAME — Kattesh V. Katti, Raghuraman Kannan, Kavita K. Katti, Satish Kumar Nune, Cathy S. Cutler, Charles Caldwell, Ravi Shukla, Nripen Chanda, Ajit Zambre and Anandhi Upendran (MU)




ANIMAL KENNEL FOR SCIENTIFIC EXAMINATION — Joan R. Coates, Teresa E. Lever, Mitchell Allen and Laila Al-Khashti (MU)


SACCHARIDE CONJUGATES — Alexei Demchenko, Michael R. Nichols and Sophon Kaeothip (UMSL)


BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE — George C. Stewart, Brian Matthew Thompson and Chung-Ho Lin (MU)



9,133,519 9,139,456

COMPOSITIONS AND METHODS FOR DIAGNOSIS OF GENETIC SUSCEPTIBILITY, RESISTANCE OR TOLERANCE TO INFECTION BY MYCOBACTERIA AND BOVINE PARATUBERCULOSIS USING PROMOTER VARIANTS OF EDN2 — Holly L. Neibergs, Ricardo Zanella, Jeremy F. Taylor, Zeping Wang, Erik Scraggs, Stephen N. White, Robert Schnabel and Curtis P. Van Tassell (MU) CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS — Robert A. Yokel, Wesley R. Harris, Christopher D. Spilling, Robert Joseph Kuhn and Surendra Dawadi (UMSL)




METHOD OF PREDICTING CROP YIELD LOSS DUE TO N-DEFICIENCY — Peter Clifton Scharf and Victoria Cacnio Hubbard (MU)




SOYBEAN VARIETY S05-11482 — James Grover Shannon, David Alan Sleper and James Allen Wrather (MU)


SOYBEAN VARIETY S06-4649RR — James Grover Shannon (MU)


TISSUE PRESERVATION SYSTEM — James L. Cook, Clark T. Hung, Eric Lima and Aaron Stoker (MU)


SUPPRESSION OF SARS REPLICATION BY SARS HELICASE INHIBITORS — Stefan G. Sarafianos, Adeyemi O. Adedeji, Kamlendra Singh (MU)




BYPRODUCTS OF GLYCEROL METABOLIZED BY BACTERIUM — Melanie Rose Mormile, Daniel William Roush, Dwayne Alexander Elias and Oliver Clifford Sitton (S&T)


GENES IMPLICATED IN RESISTANCE TO SOYBEAN CYST NEMATODE INFECTION AND METHODS OF THEIR USE — Melissa Goellner Mitchum, Pramod Kaitheri Kandoth, Greg Yeckel and Nagabhushana Ithal (MU)


Entrepreneurs with great ideas and good planning


Mentors with proven skills and experience

= A greater chance of success.

Contact us for more informaton: web: email: phone: 573.882.9582

Creating and sustaining world-class mentoring experiences for entrepreneurs and business leaders.

MBE & WBE Certification

ENGINEERING ABSTRACTS UNIVERSITY OF MISSOURI 20 Betavoltaic Battery Systems: Applications Ranging From Implantable Devices to Automobiles 20 Cochlear Microphone That Mimics Natural Hearing 20 Highly Efficient Tattoo Removal Device 20 Lithium Battery Components 20 Low-Temperature Manufacturing of ZnO Nanostructures 21

MEMS Biosensor for the Rapid Detection of Bacteria


Metasurface Microbolometers


Micro Vibrational Energy Harvester


Miniaturized X-Ray Generator


Nanocomposite Membranes With Advanced Antifouling Properties Under Visible Light Irradiation

22 New Breast Cancer Imaging Technique 22 Novel Polyconjugated Clusters 22 Osteomodulatory Hydrogels for Treatment of Osteoporosis 22 Power-Generating Threads 23 Precision and Multi-Dimensional Force Microscopy Platform With Electrophysiological Detection 23 Self-Sustained Plasma Generator 23 Trithiols and Their Arsenic Compounds for Use in Diagnostic and Therapeutic Applications 23 Ultra-High Resolution Optical Coherence Tomography (OCT) 23 ZouTread: The Central-Directional Virtual Reality Treadmill

MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY 24 Counterfeit Computer Chip Detection Method 24 Distributed Flow Battery for Transport Systems 24 Drag Reduction in Vehicles Through Surface Modifications

UNIVERSITY OF MISSOURI - KANSAS CITY 25 Solid State Neutron Energy Correction Dosimeter 25 WiFi Honk

UNIVERSITY OF MISSOURI - ST. LOUIS 25 Add-on Device for Spectrophotometer Instruments That Increases Sensitivity Up to 100-Fold 26 Novel Luminescent Materials for Improved OLEDs 26 Ultra-Sensitive Mini-spectrometers

University of Missouri



If an individual wants to have a tattoo removed, there is essentially one option: laser tattoo removal. Current practices are often painful and require numerous treatment sessions, which can be costly. This invention is a new way of introducing laser light to the skin, so a much higher efficiency can be attained. This process allows tattoos to be eliminated in fewer sessions, expands the range of skin tones that can be treated and minimizes pain. The device also is transferable to other aesthetic laser treatments such as hair removal.

Several MU research groups have used their access to the largest U.S. university research reactor to develop betavoltaic batteries. Still primarily in the prototype stage, these groups have developed betavoltaic batteries for different size and power requirements, including MEMS devices, implantable devices, cell phone, cars and even power plants. While each group’s core technology differs based on size and power requirements, all have focused on overcoming the low efficiencies that have plagued previous battery concepts. In doing so, they have developed batteries that should last for years without needing to be recharged. Potential Areas of Application: • Powering implantable devices • Powering military technologies • Powering sensors used in space or underwater Patent Status: Patents issued and pending Inventors: Several independent research groups Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

COCHLEAR MICROPHONE THAT MIMICS NATURAL HEARING This invention employs novel construct designs for hearing aids and cochlear implants. The new design enables patients with hearing loss who require amplification to enjoy their implants without frequent occurrences of unnatural sounds being produced. The key advantage of this new invention is that it allows patients to enjoy more natural sounds over the range of audible frequencies. The technology accomplishes this by transforming the input sound wave into electrical energy in an innovative fashion. Complaints of patients with hearing aids and cochlear implants are well-documented. Therefore, a significant improvement in the quality of sound heard by patients would give an implant or aid manufacturer an enormous competitive edge. Potential Areas of Application: • Hearing aids • Cochlear implants • Sound processing Patent Status: Patent pending Inventors: Hsiu-hung Chen, Chung-Lung Chen, Matthew P. Page and Arnaldo Rivera Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963


POTENTIAL AREAS OF APPLICATION: • Tattoo removal • Hair removal Patent Status: Patent pending Inventors: Paul Whiteside, Benjamin Goldschmidt, John Viator, Nickolas Golda and Randy Curry Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

LITHIUM BATTERY COMPONENTS This invention is related to chemical precursors for spray pyrolysis of powders or thin films. With this new manufacturing process innovation, we can significantly reduce the manufacturing cost of cathode materials for lithium batteries. MU has protected this invention and is now in the process of scaling the concept under a $2 million grant from the Department of Energy. Potential Areas of Application: • Lithium battery components • Lithium battery cathodes Patent Status: Patent pending Inventor: Yangchuan (Chad) Xing Contact: Brett Maland, or 573-882-1046

LOW-TEMPERATURE MANUFACTURING OF ZNO NANOSTRUCTURES Zinc Oxide (ZnO) nanostructures are becoming increasingly important because of their unique ability to harness energy — whether it be in piezoelectric crystals or a photovoltaic cell. To maximize their efficiency, however, the nanostructures must be uniform, which is difficult to do in a manufacturing environment. The process developed at MU is not only capable of producing highly uniform ZnO nanostructures, but it is scalable beyond the laboratory setting, which creates low temperatures. As a result, ZnO nanostructures can be placed on virtually any surface, including highly flexible (or curved) plastics. Potential Areas of Application: • Photovoltaics • Piezoelectric devices Patent Status: Patent pending

harvester is its ability to generate a consistent amount of power over a large range of frequencies. With this flexibility, this device should find uses in aviation, diagnostics, medicine and construction.


Potential Area of Application: • Activating sensors or devices on a variety of different machines and pieces of equipment Patent Status: Patent pending Inventors: Mahmoud Almasri and Nuh Sadi Yuksek Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

According to the Centers for Disease Control and Prevention, salmonella causes an estimated 1.2 million illnesses in the U.S. each year, which results in 19,000 hospitalizations and more than 400 deaths. Strains of salmonella can cause typhoid fever, paratyphoid fever and food poisoning. Typhoid fever, while less common in the U.S., still affects about 21.5 million people annually and causes 200,000 deaths. This technology is designed to provide rapid (within one hour) and accurate detection of salmonella at concentrations lower than 10 CFU/ml. After detection, the device is also capable of capturing the salmonella for additional lab testing. An added benefit is that it can be modified to detect bacteria such as E. coli and can be reused after proper cleaning. Potential Area of Application: • Pathogenic bacteria detection Patent Status: Patent pending Inventors: Mahmoud Almasri, Shibajyoti Dastider and Shuping Zhang Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963


MINIATURIZED X-RAY GENERATOR When compared to typical commercial X-ray sources, the piezoelectric X-ray source developed at MU offers a number of distinct advantages. Most apparent is its size. Measuring 10 mm x 100 mm and weighing just over seven grams, the piezoelectric transformer is compact, especially when compared to equipment typically found in commercial X-ray devices. MU’s piezoelectric X-ray source also is low power, requiring about one watt of electrical power to operate. The compact, low-power nature of the device suggests that it could be suitable for a portable, battery-operated X-ray source, an application that is incompatible with conventional X-ray technology. Potential Areas of Application: • Can be used in remote locations • Portable electronic X-ray source for medical, biological, geological sciences and other areas

Thermal imaging was originally developed for military applications, but as manufacturing costs have decreased, the technology is finding uses in everyday applications such as sensors for self-driving cars, an instrument that augments the vision of firefighters, a tool for building inspectors to identify structural defects, and much more. The microbolometer has been the driving force behind the acceptance of this tool, and this invention further simplifies the design, which lowers manufacturing costs while also improving performance.

Patent Status: Patent pending Inventors: Scott D. Kovaleski, James VanGordon, Brady B. Gall, Peter Norgard and Andrew L. Benwell Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-89633

Potential Areas of Application: • Uncooled thermal imaging • Thermal transport studies • Infrared gas spectroscopy Inventors: Mahmoud Almasri and Edward Kinzel Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

Membrane separation of liquids (including water) is a multi-billion-dollar industry. Advanced membranes with high antifouling performance will stimulate further growth of the industry and compete favorably with existing membrane products. Under the same operating conditions, MU’s membrane has better efficiency, uses less energy and requires less cleaning than any other membrane used for recovering or isolating water. This invention consists of the creation of novel antifouling membranes through the integration of fillers with visible light photocatalytic activity. The key characteristic of the membrane is that the surface hydrophilicity increases and the filler materials can play a role in surface cleaning through photo degradation under light irradiation. This leads to enhanced fouling resistance of the membrane to organics and biomaterials.

MICRO VIBRATIONAL ENERGY HARVESTER MU researchers have worked to develop a MEMS device that harvests electrical power from vibrations for devices and sensors in locations where wired connections would be inconvenient or unrealistic, such as contact lenses. The unique feature of this vibrational energy


Inventors: Jae W. Kwon and Baek Hyun Kim Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963



Potential Area of Application: • Removal of organic materials from hollow fiber membranes Patent Status: Patent pending Inventors: Baolin Deng and Jun Yin Contact: Brett Maland, or 573-882-1046

NEW BREAST CANCER IMAGING TECHNIQUE According to the American Breast Cancer Society, more than 230,000 new cases of breast cancer are confirmed in American women every year. Early detection of breast cancer is critical with the five-year survival rate of detected stage-1 breast cancer approaching 100 percent. Although mammography is currently a central imaging method for the detection and screening of breast cancer, the overall accuracy of this test remains low. Fluorescence mediated tomography is a non-invasive, three-dimensional biomedical imaging system based on fluorescent photon propagation inside human breast tissue. The technique provides the highest sensitivity and resolution in imaging fluorescent photons. This method can be utilized with other imaging techniques to provide significant improvements over current breast imaging technologies. Potential Area of Application: • Imaging tissues, such as breast tissue, for cancer detection Patent Status: Patent pending Inventors: Ping Yu, Lixin Ma and Harrison Knoll Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

NOVEL POLYCONJUGATED CLUSTERS Dodecaborates are extremely useful compounds having applications in the treatment of nuclear waste, drug delivery and boron neutron capture therapy. MU researchers have created novel polysubstituted dodecaborates with interesting structural, electronic and spectroscopic properties. These properties make the polysubstituted dodecaborates particularly appealing for nano and optoelectronics, photonics and new polymeric materials, as well as defense and nuclear applications. Potential Areas of Application: • Nano and optoelectronics • Polymeric materials • Photonics • Defense • Nuclear Patent Status: Patent pending Inventor: Mark Lee Jr. Contact: Brett Maland, or 573-882-1046


OSTEOMODULATORY HYDROGELS FOR TREATMENT OF OSTEOPOROSIS According to the World Health Organization, osteoporosis affects an estimated 75 million people in the U.S., Europe and Japan. This results in an estimated nine million new osteoporotic fractures each year. There are currently medications on the market to help prevent osteoporotic fractures, but results are limited and are not without side effects. Similarly, there are few good ways to induce healing at the point of fracture. Bone cement can be used to provide mechanical support, but because its properties are vastly different from bone, it adversely affects stress-loading. This technology is meant to be applied at the point of fracture and induce healing rather than simply masking the fracture. Potential Area of Application: • Osteoporotic fracture treatment Patent Status: Patent pending Inventors: Brett Ulery, Emily Cheng, Christina Goldstein and Mary Allison Josselet Contact: Brett Maland, or 573-882-1046

POWER-GENERATING THREADS MU researchers have developed a thread-based energy harvester that can be integrated in garments to power portable devices such as GPS, sensors or lights. Before these fibers were developed, the best available alternatives were piezoelectric based fibers, which are difficult to integrate into existing industrial processes and lack flexibility. MU-developed threads harvest usable electricity from the movements of the fabric while it is being worn. Additionally, researchers can start with virtually any base thread such as cotton or a synthetic, providing an environmentally friendly method to coat the threads for power generation. This should allow integration into the existing manufacturing process and does not limit the flexibility of the threads. Potential Areas of Application: • Garment industry • Illuminating clothing Patent Status: Patent pending Inventors: Jae W. Kwong, Quang Nguyen and Baek Hyun Kim Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

The ability to observe the trajectory of atomic force microscope tips can be used to image particles in threedimensions (3-D) on the nano-scale. Rapid data collection can lead to accurate imaging with little inferences made. This kind of microscopy can be done in naturally occurring environments without freezing the specimen. This technology can help in monitoring chemical and biological mechanisms, as well as protein conformations. MU researchers have created a novel way to effectively image nanoparticles in 3-D. With this device, accurate 3-D nano-images can be produced and studied in naturally occurring environments. Potential Areas of Application: • Biological imaging related to drug interactions with substrates/targets • Can be used in semiconductors with slight modifications Patent Status: Patent pending Inventors: Gavin McLean King and Krishna Prasad Sigdel Contact: Brett Maland, or 573-882-1046

SELF-SUSTAINED PLASMA GENERATOR With this invention, MU researchers have developed a method to generate a toroidal air plasma that is selfsustained. The plasma has a self-magnetized field with a circulating current that is inherent in the toroidal structure. The plasma has a lifetime that is four to 10 times longer than competing methods. The plasma is scalable to higher energies and densities and can be used for a number of advanced applications such as a fusion reactor for power generation. Potential Areas of Application: • Plasma mitigation of shock waves • Directed energy applications Patent Status: Patent pending Inventor: Randy Curry Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

TRITHIOLS AND THEIR ARSENIC COMPOUNDS FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS The present invention is directed to a series of stable radioisotope trithiol complexes that provide a simplified route for the direct complexation of radioisotopes present in low concentrations. In certain embodiments, the complex contains a linking domain configured to conjugate the radioisotope trithiol complex to a targeting vector. The invention is also directed to a novel method of linking the radioisotope to a trithiol compound to form the radioisotope trithiol complex. The inventive

radioisotope trithiol complexes may be used in a variety of applications, including diagnostics and treatment in nuclear medicine, due to the unique and promising characteristics of radio-arsenic.



Potential Areas of Application: • Therapeutic tool • Tracking agent in radiopharmaceuticals • Multiple areas of science can use this technology Patent Status: Patent pending Inventors: Silvia Jurisson, Anthony DeGraffenreid and Cathy Cutler Contact: Brett Maland, or 573- 882-1046

ULTRA-HIGH RESOLUTION OPTICAL COHERENCE TOMOGRAPHY (OCT) Adequate detection and analysis of the choroidal thickness and other structures in the eye are critical to the accurate and successful diagnosis of eye diseases. However, current optical coherence tomography technology is limited in resolution and penetration depth due to the use of a Gaussian beam. The current invention modifies the light sources used in current systems such that the instrument can see deeper into the eye and also improve the image resolution. The improved quality of images produced should support better diagnosis and treatment of optical diseases. Potential Areas of Application: • OCT imaging devices • Superior diagnosis ability Patent Status: Patent pending Inventors: Ping Yu and Lixin Ma Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963

ZOUTREAD: THE CENTRAL-DIRECTIONAL VIRTUAL REALITY TREADMILL ZouTread is a central-directional treadmill for gradual turning in the range of +/- 30 degrees. The uniqueness of this invention focuses on the integration of four main components: torso tracker, display, treadmill and simulator engine. The user’s direction of movement is captured by measuring the torso’s rotation with respect to the forward direction. ZouTread also incorporates an optimized display to provide an immersive environment. Potential Areas of Application: • Exercise and rehabilitation • Video gaming • Training and simulation Patent Status: Under evaluation Inventors: Carlos Sun, Praveen Edara, Charles Nemmers and Bimal Balakrishnan Contacts: Wayne McDaniel, or 573-884-3302; Eric Barmann, or 573-882-8963 23

Missouri University of Science & Technology COUNTERFEIT COMPUTER CHIP DETECTION METHOD Globally manufactured and mass-produced electronic devices and components touch every business and consumer in the world today. However, counterfeit electronic devices and components contribute to lost revenues, lost productivity and numerous other hassles. The inventive process from S&T researchers employs a combination of new and innovative electromagnetic (EM) signature evaluation techniques to determine authenticity of electronic integrated circuits (ICs), and other passive and active electronic devices and components. The process evaluates the intrinsic and unique characteristic electromagnetic (EM) signature from a known “good” device or a component and uses this EM signature to differentiate counterfeits. Our research accounts for the diversities and the potential degrees of variability that may exist for a particular electronic device or component (i.e., packaging material properties, electronic circuit design layout, etc.) The distinction between “acceptable” and “unacceptable” components may not be robustly accomplished in a deterministic fashion. In such complex cases, the distinction will be statistical in nature - for example, the characteristic EM “signature” of a component may be statistically compared to the EM signature of an “acceptable” group of the same device. In this way, a “metric,” related to the differences between the two classes of EM signatures can be established by which to determine and decide on the device’s acceptability. The process can evaluate a device either in the “powered-on” or “powered-off” modes, with evaluation time ranging in the order of fractions of a second to a short few seconds depending on the evaluation technique. Potential Areas of Application: • Detection of counterfeit IC (Integrated Circuits) • Quality control for IC manufacturing • Aging of IC’s Patent Status: Patents pending Inventors: Reza Zoughi, Mohammad Tayeb Ghasr, Satyajeet Shinde and Sasi Jothibasu Contacts: Keith Strassner, or 573-341-6725; John Woodson, or 573-341-7544

DISTRIBUTED FLOW BATTERY FOR TRANSPORT SYSTEMS Robust and efficient energy storage systems are key to advancing transport systems such as electric vehicles, robots and the like. Conventional transport systems use lithium-ion batteries for energy storage that suffer from disadvantages of lengthy recharge times, bulkiness and a relatively short life due to mechanical and/or chemi24

cal degradation. Moreover, lithium-ion batteries require increasingly large physical sizes (e.g., volume) for adequate power generation for vehicles. S&T’s inventive energy storage system has a reaction cell configured for distribution throughout a transport system. Aspects of this invented distributed flow battery use flow battery reaction cells configured for distribution throughout a transport system to increase electrical power by maximizing membrane surface area relative to reaction cell volume. By distributing the flow battery system throughout the vehicle, the invention provides better efficiency, more power, has quicker charge time, and deeper discharge relative to lithium-ion batteries and conventional flow batteries. The length of the reaction cell is substantially greater than its width and is looped throughout the transport system in a serpentine configuration. A membrane within the reaction cell has a length substantially equal to the length of the reaction cell such that surface area of the membrane is maximized relative to volume of the reaction cell to increase electrical power provided to an electrical load of the transport system. Potential Areas of Application: • Energy storage • Electric vehicles Patent Status: Patents pending Inventors: Johghyun Park and Mohammed Al-Yasiri Contacts: Keith Strassner or 573-341-6725; John Woodson, or 573-341-7544

DRAG REDUCTION IN VEHICLES THROUGH SURFACE MODIFICATIONS Airlines and aircraft manufacturers have tried many things in recent years to increase efficiency and decrease fuel costs for air travel. After all, all businesses strive for efficiency, and efficiency is improved through technological advances. Drag is a major contributor to inefficiency and fuel usage for air travel. S&T researchers have invented a process aimed at reducing or eliminating skin friction drag by tailoring the structural details of the surface and by appropriately minimizing the resultant pressure drag penalty. This recently invented process is aimed at reducing or eliminating skin friction drag within defined regions on surfaces. Specifically, by generating very small and successive fluid separation regions within micro-cavities that are structurally imbedded within the surface of the vehicle with suitable modifications and requirements, the skin friction drag can, in principle, be eliminated or even realized as a net contribution to thrust. Results using computational fluid dynamics show significant across-the-board reductions in overall drag (15% to 50%) are conceptually possible on flat planes using the basic concept. Drag reductions should apply across a wide Mach number range and, hence, may apply for many different systems and applications. Techniques and concepts such as these imbedded micro-cavities can generate significant reductions in skin friction drag

Potential Areas of Application: • Aircraft and spacecraft design • Energy efficient vehicle design Patent Status: Patent issued Inventor: David Riggins Contacts: Keith Strassner, or 573-341-6725; John Woodson, or 573-341-7544

University of Missouri Kansas City SOLID STATE NEUTRON ENERGY CORRECTION DOSIMETER A neutron detection system may include a neutron detector including a plurality of neutron detection devices, a plurality of discrete neutron moderating elements, wherein each of the neutron moderating elements is disposed between two or more neutron detection devices, the plurality of neutron detection devices and the plurality of discrete neutron moderating elements disposed along a common axis, a control system configured to generate a detector response library, wherein the detector response library includes one or more sets of data indicative of a response of the detector to a known neutron source, receive one or more measured neutron response signals from each of the neutron devices, the one or more measured response signals response to a detected neutron event, and determine one or more characteristics of neutrons emanating from a measured neutron source by comparing the one or more measured neutron response signals to the detector response library. Potential Areas of Application: • Defense • Nuclear Patent Status: Patent issued Inventors: Anthony Caruso, Tom Oakes and William Miller Contact: Eric Anderson, or 816-235-5091


As pedestrians increasingly engage in activities such as listening to music, watching videos, gaming and making calls with their smart devices while walking, they are at risk of getting involved in accidents with vehicles. There are several pedestrian safety mechanisms now deployed on the streets to reduce the risk of vehicle-to-pedestrian collisions. However, all such mechanisms are passive in nature and not capable of sending individual pedestrians alerts tailored for their specific scenarios.

Researchers at UMKC have developed an active safety mechanism called Wi-Fi Honk that uses Beacon Stuffing to alert pedestrians of possible collisions while using smart devices. Vehicles activate their WiFi Hotspot/Direct mode and set their SSID or BSSID in a specialized format of a Wi-Fi Honk Information Packet (WHIP). The information in the WHIP is used to compute the precise direction vector of the vehicle. A pedestrians’ smart device acts in Wi-Fi discovery mode. Once it encounters a meaningful Wi-Fi Honk message in the SSID/BSSID segment of the scanned APs, it extracts the WHIP and populates in its database in a tabular format that is sorted in order of lowest time to collision (ToC). The pedestrian’s smart device uses its own location, speed and direction of travel to compute its direction vector, and it then generates a logical map by mapping its own vector along with the direction vectors for various vehicles obtained through Wi-Fi Honk. When the ToC for a particular entry reaches a predetermined critical point, the device alerts the pedestrian with audio, tactile and visual alerts via the smart device’s headphones/speakers, vibrations and display screen.


and are of vital importance to fuel economy, vehicle design, and optimization, therefore increasing mileage and decreasing costs, hence increasing efficiency.

Potential Areas of Application: • Geolocation communication and accident prevention between vehicles and pedestrians or bicycles with smart devices • Geolocation communication, accident prevention, and synchronization between multiple vehicles Patent Status: Patent pending Inventors: Baek-Young Choi, Sejun Song and Dhondge Kaustubh Contact: Melanie Roberts, 816-235-5090 or

University of Missouri St. Louis ADD-ON DEVICE FOR SPECTROPHOTOMETER INSTRUMENTS THAT INCREASES SENSITIVITY UP TO 100-FOLD Researchers at UMSL have developed a device that can be internally or externally integrated into current spectrophotometer instruments to increase sensitivity by up to 100-fold, allowing for measurements of substances at much lower concentrations than is possible with current instrumentation. Spectrophotometer sensitivity is determined by signal to noise ratio (S/N), which should be as large as possible. This technology increases the S/N using a novel feature in the detector circuitry to significantly reduce the noise level while maintaining a constant signal. Potential Areas of Application: • UV-Vis, FTIR, Atomic absorption and HPLC • Circular sichroism and Capillary electrophoresis


Patent Status: Patent pending Inventor: Zhi Xu Contact: Craig Weilbaecher, or 314-516-4248

NOVEL LUMINESCENT MATERIALS FOR IMPROVED OLEDS Efficient, stable blue-emitting materials are uncommon, which is seriously handicapping the multi-billion dollar display technology market. Researchers at UMSL have a synthetic method to produce new germanium compounds that demonstrate highly efficient solid-state, blue-emitting luminescence. These compounds exhibit aggregated induced emission (AIE) in the visible blue to blue-green region making them ideal candidates for blue-emitting components in solid-state, organic light-emitting diode (OLED) applications. Eighteen germanium-containing derivatives have been synthesized and characterized to date. The university has provided commercialization funds to support validation and prototyping of the technology with a commercial partner. We are seeking a commercial partner for further development and potential licensing. Potential Areas of Application: • Materials for chemical and biological sensors • Solar cells • Oganic light-emitting diode components and thin- film transistors for TV/computer/cell phone displays

Patent Status: Patent pending Inventors: Janet Wilking, Teresa Bandrowsky and James Carroll Contact: Craig Weilbaecher, or 314-516-4248

ULTRA-SENSITIVE MINI-SPECTROMETERS The miniaturization of typically large lab instruments is finally becoming a reality. Miniature optical spectrometers based on linear silicon CCD array detectors have been around for decades. However, the sensitivity of the CCDbased spectrometer is low (only 250:1 for USB2000 made by Ocean Optics). An UMSL researcher has developed a multichannel ultra-sensitive optical spectrometer that combines the advantages of a compact size with higher sensitivity (50 to 100-fold) over detectors currently on the market. The new mini-spectrometers would bring the power of benchtop instruments into the hands of law enforcement officers, TSA agents and field researchers. Potential Areas of Application: • More cost-effective instruments for research labs • Portable, hand-held spectrometers for first responders and TSA agents • Compact, robust instruments for field researchers Patent Status: Patent pending Inventor: Zhi Xu Contact: Craig Weilbaecher, or 314-516-4248

The University of Missouri Interdisciplinary Center on Aging joins MU researchers, health providers, and educators who are working to improve the lives of older adults. Through collaboration, scholarly exploration, teaching, and leadership, the Center enhances the health and well-being of elders in Missouri and beyond. Our Center serves as a hub for 98 faculty members conducting scholarly research and teaching in the field of aging. Over 40 Center fellows are principal investigators on aging research and training grants totaling over $70 million during the last four years. Monthly seminars on aging and a small grants program help advance the research of junior faculty members and graduate students. Collaboration with aging-related community agencies has positioned the Center to translate a comprehensive body of knowledge, expertise, and scholarship to improve the lives of older Americans. 

Our mission is to enhance the health and well-being of elders through research, teaching and leadership in education.

Our vision is to be a recognized source for expertise in aging issues.

Our values include collaboration, scholarship, integrity, compassion, and respect.




Fine Print

Organovo, a start-up company whose origins began at the University of Missouri, creates three-dimensional human tissue through bioprinting to advance medical research.

Organovo uses three-dimensional bioprinting to create fully functional human tissues, giving researchers an unprecedented opportunity to test drug safety and efficacy before administering the drug to a living person. The technology also provides new models for disease research and can even create new tissues to replace damaged tissue inside the human body. The company was originally founded by MU researcher Gabor Forgacs, a self-described “theoretical physicist turned biological physicist, turned tissue engineer, turned entrepreneur.� His pioneering observations on wing development in chicks led to a desire to model embryonic cell development – eventually morphing into

the technology that puts Organovo at the forefront of tissue printing. Organovo collaborates with pharmaceutical companies and other partners to advance medical treatments. It has garnered particular attention for its first-in-class liver tissue assay, with cells that last for over 40 days, allowing a broad range of toxicities enough time to develop. The company also creates lung, skin and kidney tissues, as well as blood vessels, nerve guides and cardiac patches. Dr. Gabor Forgacs is an professor emeritus of bioengineering in the Colleges of Engineering and Agriculture, Food and Natural Resources.

DALTON CARDIOVASCULAR RESEARCH CENTER 1500 Research Park Drive, Columbia, MO 65211 Telephone: 573-882-9482 Web page: Email:

Competencies in Cardiovascular Biology and Medicine •In vivo and in vitro study of the circula�on •Microcircula�on •Cardiac development and pathology •Neural and humoral control of the circula�on •Angiogenesis in cancer •Disease models •Live cell imaging •Ion channels •Cellular transport mechanisms •Molecular modeling

Core �acili�es and Experimental Approaches •Fluorescence microscopy •Confocal and mul�photon microscopy •Atomic force microscopy •�D imaging and reconstruc�on •In vivo microscopy •High resolu�on ultrasound and photoacous�c imaging •Brain slice imaging •Neuronal tracking •Patch clamp •Molecular and cell biology


HEALTH SCIENCES ABSTRACTS UNIVERSITY OF MISSOURI 30 30 30 31 31 31 32 32 32 32 33 33 33 34 34 34 35 35 36 36 36 36 37

Antiviral Compounds for the Treatment of Coronaviruses Such as SARS, MERS and MHV Constrained Prosthetic Acetabulum Device and Technique for Tibial Plateau Allografting With or Without Attached Meniscus Device to Assist Delivery of the Well-Applied Fetal Head at Cesarean Section Dual Colorimetric-Fluorescent Sensor for Early Detection of Diabetic Retinopathy: DR-Sensor Electrocardiogram (ECG) Biomarkers for Pre-Symptom Detection of Infectious Diseases Element 1 Antisense Morpholinos Gene Therapy Gold Nano Rod-Based Diagnostic Platform Hybrid Synthetic Biologic Joint Arthroplasty Systems Improved Dual Gold-Iron Alloy Nanoparticle Conjugates for Selective Separation of Globin or Trophoblast Cells From Biological Matter and Methods Instrument to Close Fascia During Laparoscopic Surgery Nano-Ayurvedic Medicine Through Green Nanotechnology Production of Gold Nanoparticles Using Traditional Ayurvedic Principles New Surgical Tools and Techniques to Make Patient Anatomy-Specific Osteochondral Grafts Possible Novel Nano-Graft Designed to Improve the Efficacy of ACL Reconstruction Novel Sodium Channel Blockers Novel Dystrophin Membrane-Binding Domains (MBDs) Optical Polarization Tractography: A New High-Resolution Imaging Technology for Early Detection of Diseased Tissues Osteoarthritis Biomarker Panel Osteochondral Allografts for the Ankle Shell Cutter Instrumentation for Patient-Specific Osteochondral Allografts Stem Cells Synergize With Immune Modulation for Treatment of Type I Diabetes Sustained Delivery of Therapeutic Agents to the Retina Targeted Nano Platform for Delivery of siRNA and Drug 37 Tool and Process Alignment and Site Preparation of Novel Rotator Cuff Grafts

UNIVERSITY OF MISSOURI - KANSAS CITY 37 Biocompatible Bone Cement 37 Dental Etching Gel With Collagen-Stabilizing Functionality 38 Light-Activated Insulin Depot 38 Solubility-Enabling Coating for Pharmaceuticals

UNIVERSITY OF MISSOURI - ST. LOUIS 38 Detecting and Treating Tb Using Lipase Inhibitors 39 Novel Bis-Amino Acid-Based Compounds to Recover or Enhance Efficacy of Existing Antimicrobials


University of Missouri ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF CORONAVIRUSES SUCH AS SARS, MERS AND MHV The current invention developed at MU presents a unique technology for the treatment of coronavirus infections, which currently have no approved treatments. This technology involves a new class of enzyme inhibitors of coronavirus replication that block the helicase activity of a specific region of the virus. These helicase inhibitors block the nucleic acid unwinding activity of the virus to prevent the spread of viral infection. Coronaviruses, such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and related viruses present the real possibility of future outbreaks based on past coronavirus epidemics. Coronaviruses are a group of RNA viruses responsible for illnesses ranging from the common cold to deadly infections. SARS is a highly contagious and sometimes life-threatening infection caused by the SARS-CoV coronavirus. MERS is a severe acute respiratory illness that is caused by the MERS-CoV coronavirus. Both of these illnesses carry high mortality rates and currently have no approved treatments or vaccines. Coronaviruses, such as the type that causes Mouse Hepatitis Virus (MHV), also affect animals and frequently result in death. The current technology presents novel antiviral compounds for the treatment of these previously untreatable viral infections. Potential Areas of Application: • SARS, MERS and MHV antiviral • Broad spectrum antiviral against many other coronaviruses Patent Status: Patent issued Inventors: Stefan G. Sarafianos, Adeyemi O. Adedeji and Kamlendra Singh Contacts: Samuel E. Bish, or 573- 882-5016; Nancy Parker, or 573-884-3553

CONSTRAINED PROSTHETIC ACETABULUM Dislocations can be a painful and expensive outcome after artificial hip replacement. This inventive prosthetic is a constrained ball-and–socket joint and is designed to prevent dislocations. The prosthetic consists of a D-shaped femoral head with the flat surface capable of attaching to any commercially-available femoral stem, a concave cavity liner that is slightly more than a hemisphere, i.e. the edges extend beyond the equatorial plane and a shell cavity is compatible to the liner. The device’s unique liner design allows for the femoral head to be inserted at a particular alignment and rotationally constrained within the liner. In essence, the ball is keyed into the socket by virtue of its unique design and, much like a key in a door lock, any rotation of the head away from the point of insertion creates inherent stability in the construct, precluding component dislocation.


Potential Area of Application: • Hip replacement Patent Status: Patent pending Inventors: Sonny Bal, Mohamed Rahaman and Mitch Tarka Contact: Charlie Hanford, or 573-882-0477

DEVICE AND TECHNIQUE FOR TIBIAL PLATEAU ALLOGRAFTING WITH OR WITHOUT ATTACHED MENISCUS This invention, developed by MU researchers, is a unique surgical instrumentation system that allows for standardized preparation of a tibial allograft from donor tissue with precisely matched preparation of the patient’s proximal tibia to receive a meniscal-tibial plateau allograft. This technology has the potential to revolutionize knee surgery by allowing for biological joint replacement of this difficult-to-treat region of the knee, increasing the use of organ donor tissue and improving outcomes for patients with this common knee problem. Currently, patients with extensive damage to their tibial articular cartilage and/or meniscus in the knee have few treatment options that allow them to return to highly functional activities. Current standard-of-care allograft cartilage and meniscus transplantation techniques do not address these types of extensive injuries due to limitations in surgical site access, effective instrumentation and stabilization of viable and functional tissues. Complications arising from graft functionality, placement, and fixation to the tibia (as well as functionality of the underlying tibial cartilage) also inhibit success of current methods. Total and partial joint replacements using synthetic materials also do not allow return to these activities and have a limited functional lifespan. Younger, active patients want better options as surgeons search for biological treatments that consistently provide them with more optimal outcomes. MU’s technological advancement has the potential to address all of these limitations. Potential Areas of Application: • Human orthopaedic surgery • Veterinary medicine – orthopaedic surgery Patent Status: Patents pending Inventors: Ferris Pfeiffer, James L. Cook and James P. Stannard Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

Caesarean sections are the most common major operation performed in the U.S. and the industrialized world. Arrest disorders affect up to 20 percent of labors and are the most common indication. Between 100,000 to 400,000 of the deliveries can be complicated by a strong seal formed between the fetal head and the lower uterine segment (“well-applied” fetal head) during the second stage of labor. The breaking of such a seal is difficult, requires additional procedures, presents risk to the fetus and can introduce vaginal bacteria into the patient’s uterine cavity. This invention is a novel obstetric device designed to assist in the delivery of the “well-applied” fetal head during caesarean section. The device is crafted of sterile, pliable material designed to allow a surgical assistant to easily and comfortably palpate the fetal head and break the suction between the head and the lower uterine segment. The device decreases the force needed to facilitate delivery and reduces potential trauma to the mother and fetus. Potential Area of Application: • Caesarean section delivery Patent Status: Patents issued and FDA-approved Inventors: Breton F. Barrier and Gary F. Clark Contact: Charlie Hanford, or 573-882-0477

DUAL COLORIMETRIC-FLUORESCENT SENSOR FOR EARLY DETECTION OF DIABETIC RETINOPATHY: DR-SENSOR Diabetic retinopathy (DR) is a major micro-angiopathic complication that arises in both Type 1 and Type 2 diabetic patients. According to International Diabetes Federation (IDF) 2013 statistics, nearly 8.3 percent of adults (382 million people) have diabetes, and that number is expected to exceed 592 million in less than 25 years. DR damages the blood vessels in the retina resulting in vision loss or blindness. In fact, DR is considered a major cause of blindness in both Indian and American adult populations. The prevalence of DR shows large variations globally. Depending on the severity of the disease, DR is classified in four stages: mild, moderate, severe and proliferative retinopathy. Although the complications are overwhelming, patients even in an advanced stage of DR often show no symptoms. Vision loss is preventable by timely detection and treatment; therefore, diabetic patients are required to have frequent eye exams. A typical eye exam in diabetic patients includes a visual acuity test, a dilated eye exam and tonometry. These tests are expensive and time-consuming. An in-home sensor could solve this problem, but developing a sensor requires a validated biomarker that needs to be secreted by urine, or other body fluids. A simple nanotechnology-based sensor for in-home applications

will help in early detection of diabetic retinopathy patients and help prevent vision loss for diabetics. MU researchers have developed an in-home sensor for early detection of diabetic retinopathy. It features a test strip onto which a sample of urine is placed, and a positive test result is indicated by the appearance of a fluorescent red color on the test portion when exposed to a hand-held UV light source. Results are obtained in less than 10 minutes.



Potential Area of Application: • Early detection of diabetic retinopathy Patent Status: Patent pending Inventors: Raghuraman Kannan, Sandhya Saranathan, Anandhi Upendran and Uzma Khan Contact: Charlie Hanford, or 573-882-0477

ELECTROCARDIOGRAM (ECG) BIOMARKERS FOR PRE-SYMPTOM DETECTION OF INFECTIOUS DISEASES This invention from MU uses electrocardiogram (ECG) to identify intervals in an individual’s heart rhythm as biomarkers for pneumonic plague and other infectious diseases. Device applications of this ECG biomarker technology can be used to identify exposure to infectious agents befoe the onset of detectable disease symptoms. This technology also has the potential to identify ECG biomarkers that can correlate responses of protective and non-protective therapeutic treatments. Traditional methods of testing for pathogens and other infectious agents can take up to 72 hours to obtain reliable results. More rapid methods of detection are needed to combat fast disease progression and transmission of the infection. Currently available methods for rapid detection of pathogens include various kinds of PCR that involve expensive DNA extractions and sometimes the inability to confirm bacterial viability in the test sample. Therefore, implementing a more cost effective and rapid method to detect exposure to infection before the onset of symptoms would enable more timely and effective treatment of affected individuals. Potential Areas of Application: • Non-invasive and efficient hardware and software applications to identify oncoming and progressing infectious diseases • Wearable bio-warfare technology for military to detect exposure to infectious agents • Evaluate the success of various therapies for infectious diseases during the course of treatment Patent Status: Patent pending Inventors: Deborah Anderson, Eric Coate, Miqdad Dhariwala and Joshua Willix Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553


ELEMENT 1 ANTISENSE MORPHOLINOS GENE THERAPY Spinal Muscular Atrophy (SMA) is a lethal genetic disease in infants that causes degeneration of SMN protein in the spinal cord. In humans, SMN protein is produced by a gene called Survival Motor Neuron 1 (SMN1). Loss of the SMN1 gene in newborns leads to the development of SMA and ultimately death. An identical gene to SMN1 – known as Survival Motor Neuron 2 (SMN2) – is expressed in humans, but can only make a fraction of SMN protein. SMN2 lacks a final coding exon (exon 7) that permits SMN1 to create an abundant amount of SMN protein. However, infants with SMA retain a copy of SMN2, thereby making an ideal target to modulate its splicing patterns and produce more SMN protein. MU’s invention uses morpholino chemistry to create an SMN2-specific antisense oligonucleotide (ASO). This antisense oligonucleotide anneals to a repressor region of SMN2 exon 7 called Element 1 (E1). Uninhibited E1 activity leads to the reduced production of SMN protein by the SMN2 gene. The antisense oligonucleotide blocks E1 repressive activity and allows the SMN2 gene to express large amounts of SMN protein. This gene therapy can help replenish the defect of SMN protein seen in infants with the disease. Potential Area of Application: • Pharmaceutical companies developing SMA-specific therapies Patent Status: Patents pending Inventors: Christian Lorson and Erkan Osman Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

GOLD NANO ROD-BASED DIAGNOSTIC PLATFORM Gold Nano Rod HistoChemistry (GNR-HC) is a platform technology. The technology can be extended to biomarkers of interest in cancers and other pathologies by careful variation of the biomolecule attached with the nanoparticles. In addition to histochemical detection of tissue proteins, this methodology also has the capacity to identify RNA and DNA in situ. MU’s team has applied GNR-HC for identifying and quantifying EGFR-expression (EGFR-Sure) and c-MET expression (cMET-Sure) in a human tissue sample. The technology employs a synthetic biomolecule that is anchored to gold nanorods. The biomolecule is highly selective for binding to the targeted protein, and the gold nanorods provide a unique imaging agent. The combination of gold nanorods with bound ligands specific for binding to EGFR provides a simple “stain” that quickly allows a histologist to determine if a tumor is over-expressing EGFR. The use of a metal nanoparticle provides a reproducible intensity that will not diminish with repeated observation allowing repeat cataloging of results. In addition, the technique is highly specific, costeffective and user-friendly.


Potential Area of Application: • Tumor analysis and diagnosis of other diseases Patent Status: Patent pending Inventors: Raghuraman Kannan, Mythili Ramachandran, Charles W. Caldwell, Charles W. Caldwell, Jr., Nripen Chanda, Ajit Prakash Zambre and Gerald Arthur Contact: Charlie Hanford, or 573-882-0477

HYBRID SYNTHETIC BIOLOGIC JOINT ARTHROPLASTY SYSTEMS The current invention developed by MU researchers comprises a group of related implants, instruments and techniques that provide a variety of options for performing joint replacement and resurfacing surgeries. The implants will be composed of a synthetic component and a biologic component. The hybrid implants are designed to optimize long-term success in joint replacement and resurfacing surgery of all major joints by combining the advantages of synthetic and biologic arthroplasty techniques while minimizing the disadvantages of each. The demand for joint replacement surgeries is expected to rise exponentially in the coming years, based on rising elderly populations and an increase in a sedentary lifestyle in the United States. However, existing methods of implanting joint replacements are not capable of measuring forces from a variety of real-life impact situations and cannot be tailored to an individual patient’s needs. Potential Areas of Application: • Treatment for focal cartilage defects of the knee, ankle, elbow and shoulder • Partial and complete hemi-arthroplasties for trauma or arthritis • Total joint arthroplasty of the knee, shoulder, hip, ankle, elbow, wrist, TMJ, fingers and toes for trauma and/or arthritis Patent Status: Patents issued and pending Inventors: James L. Cook, Clark T. Hung, Gerard Ateshian, Eric Lima and Li Ming Bian Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

IMPROVED DUAL GOLD-IRON ALLOY NANOPARTICLE CONJUGATES FOR SELECTIVE SEPARATION OF GLOBIN OR TROPHOBLAST CELLS FROM BIOLOGICAL MATTER AND METHODS Based on the current available technique, the inventors have developed a method for selective isolation of globin or trophoblast cells from biological matter using core-shell magnetic nanoparticles containing multiple copies of antibodies on the surface. The selective separation is based on antigen-antibody interaction of nanoparticles. The material used for separation contains multiple copies of a selected antibody on the surface with high affinity toward a chosen antigen of interest. Globin or trophoblast cells separated from the bio-

INSTRUMENT TO CLOSE FASCIA DURING LAPAROSCOPIC SURGERY After a laparoscopic surgery procedure, a surgeon must often accurately close a trocar port site in the anterior abdominal wall following removal of a large trocar cannula from the port site. Failure to close the site, or an improper closure of the port site can sometimes lead to a herniation of the bowel and subsequent bowel obstruction. Because the standard closure technique for the trocar port site is through a small incision, the present mode for closure of a trocar port site is to reach down to the desired tissue layer with pickups and a loaded needle driver to grasp the needle through the abdominal wall and withdraw it with the pickups to secure a stitch across the port site. Many times the skin incisions must be extended to accomplish suturing the port site closed. This surgical instrument can be introduced through a current trocar puncture site. Using a “pitch and catch” mechanism, the device places a suture in the deep fascia and peritoneum of the anterior abdominal wall, reducing needle sticks and resulting in a more complete closure of the site. It is a lightweight and easy-to-use instrument that can be operated quickly and efficiently to close a trocar puncture wound simply and economically. Potential Area of Application: • Laparoscopic surgery closures Patent Status: Patent pending Inventors: Jaya Ghosh, Ellie Koehly, Yaw Sarpong and Roger de la Torre Contact: Charlie Hanford, or 573-882-0477



logical matter retain structural and biological identity and are therefore ready to be investigated by conventional analytical techniques. The method described for selective separation and enrichment of analyte is adequate for subsequent analysis. The separation of globin from the feces enables early detection of colorectal cancer. In similar fashion, separation of trophoblast cells obtained from a vaginal swab (or other biological matter) aid in subsequent genetic analysis of cells for predicting the health of a baby. Potential Areas of Application: • Separation of globin for analysis • Separation of trophoblast cells for analysis Patent Status: Patent pending Inventors: Raghuraman Kannan, Sandhya Saranathan, Anandhi Upendran and Shreya Ghoshdastidar Contact: Charlie Hanford, or 573-882-0477

Ayurvedic medicine is an ancient healing modality originating in India about 5,000 years ago. This medical system advocates holistic principles to achieve prevention and curative therapies to restore balance in the human body, prevent long-term illness and to promote natural wellness. In most countries, Ayurveda medicine is still considered an “alternative” medical modality. However, in the U.S., Germany and Japan, Ayurveda is gaining prominence because of its inherent power of providing a healing mechanism addressing the entire body to treat diseases by identifying primary causes of illness — all with minimal or no toxic side effects. Globally, Ayurvedic medicine has penetrated less than 2 percent of the population, suggesting an unprecedented growth potential for this important medical modality. Ayurveda medicines are always administered in combination with herbs, metals and metal ions (in the form of ash or referred to as “Bhasma” in the Ayurvedic literature). Gold ash, mixed with a cocktail of herbs, has been extensively used in the treatment of cancer, arthritis (both osteo and rheumatoid), various infectious diseases and also in opening-up blocked arteries in cardiovascular therapy. Gold ash formulations are also used in treating various neurological disorders. The undefined chemical formulations of gold ash have always resulted in irreproducible chemical species causing high unpredictability in administering the welldefined active ingredient through scientifically acceptable measured doses. These challenges have resulted in high toxicity of metallic species, or sometimes less than optimal bioavailability of biologically active species – all causing significant challenges for wider acceptability by regulatory agencies such as the U.S./European FDAs. This invention reports on the discovery of herballyinitiated, green nanotechnology-derived, production of gold nanoparticles using strict ‘Ayurvedic Principles’ (without the use of any toxic or man-made chemical). The process is 100 percent reproducible, and scale up for commercial production has also been achieved, thus paving the way for the rapid expansion and wider acceptability of the field of Ayurvedic medicine through our new approach referred to as ‘Nano-Ayurvedic Medicine.’ Our green nanotechnology approaches will rejuvenate Ayurveda medicine to provide universally acceptable medical standards for launching a series of Ayurnano products for treating a myriad of human diseases and disorders. Potential Areas of Application: • Cancer therapy • Arthritis Patent Status: Patent pending Inventors: Kattesh Katti, Menka Khhobchandani, Kavita Katti, Chintamani Joshi and Vinay Mutalik Contact: Charlie Hanford, or 573-882-0477 33

NEW SURGICAL TOOLS AND TECHNIQUES TO MAKE PATIENT ANATOMY-SPECIFIC OSTEOCHONDRAL GRAFTS POSSIBLE The current invention developed by MU researchers includes the surgical instrumentation and method for creating custom anatomic osteochondral allografts (OCA), or autografts to treat damaged areas of joints. The revolutionary instrumentation allows for contouring of grafts to the patient’s anatomy and precise preparation of the recipient site for an OCA (or autograft of complex geometry), rather than simple cylindrical grafts as currently performed. Between 600,000 and 900,000 patients in the U.S. undergo surgical treatment for articular defects resulting from osteochondritis dessicans, injury, trauma and osteoarthritis. Currently, surgeries using OCA (or autograft) comprise a small portion of the total number of procedures performed to treat these conditions due to their limitations. Though current allografts/autograft techniques are relatively easy to perform, they are not optimal for treating large articular defects in joints with complex geometries. The use of cylindrical grafts for these types of joint damage results in sub-optimal use of donor tissues, inability for anatomic reconstruction of defects, comprised graft stability and removal of significant amounts of healthy cartilage to replace all damaged tissue. All of these downfalls can lead to unsuccessful outcomes for patients, such as graft failures and disease progression, mainly due to the function of the non-patient-specific geometry of a standard cylindrical OCA (or autograft). MU’s technology is predicted to overcome current OCA and autograft procedural pitfalls to improve outcomes and increase the number of patients who can be effectively treated with OCA and autografts. Potential Area of Application: • Human or veterinary orthopaedic surgery (treating focal cartilage defects in joints) Patent Status: Patent pending Inventors: Ferris Pfeiffer, James L. Cook and James P. Stannard Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

NOVEL NANO-GRAFT DESIGNED TO IMPROVE THE EFFICACY OF ACL RECONSTRUCTION An anterior cruciate ligament (ACL) is one of the most commonly injured ligaments of the knee. A current problem experienced by many ACL-reconstruction patients is joint instability caused in part by lack of cellular integration and remodeling, leading to deterioration of the graft. Thus, there is a critical need for a new graft material that promotes cellularity, integration and recapitulation of natural joint function. This new nano-graft may provide joint stability in ways superior to existing grafts for soft tissue repair. MU’s team has developed a patented technology where nanomaterials are conjugated to a cellular tissue. The nanomaterials provide a 3-D tissue network that 34

has enhanced remodeling and controlled degradation. In addition, the innovative material promotes cellular ingrowth and provides good mechanical behavior, which will improve with time due to the recapitulation of tissue and ligament remodeling. The transformative technology uses a functionally graded nano-graft. The nanograft material is a platform technology. Potential Areas of Application: • ACL reconstruction • PCL and MCL reconstruction • Soft tissue replacement, such as rotator cuffs • Achilles, patellar, quadriceps and biceps tendons Patent Status: Patent pending Inventors: Sheila Grant, David Grant, Richard White, Sharon Bachman, Daniel Grant and Matthew Cozad Contact: Charlie Hanford, or 573-882-0477

NOVEL SODIUM CHANNEL BLOCKERS A new family of voltage-gated sodium channel blockers has been synthesized that potentially provides therapeutic alternatives to currently used analgesics, antiarrhythmics, anticonvulsants and antidepressants. The sodium channel is an integral part of nerve and cardiac cell conduction pathways. The small, structurally unique sodium channel blockers described here differ from current sodium channel blockers such as lidocaine. Preliminary studies of the physiology and neurobehavior of these compounds show that they are functional sodium channel blockers. In cell expression studies these compounds block brain type sodium channels in a manner typical of local anesthetics. These compounds provide analgesia after sciatic nerve injection and have a longer duration of action than lidocaine in vivo. Importantly, their unique structures make them poised to show selectivity among sodium channel subtypes in excitable cells. Potential Areas of Application: • Inflammatory and neuropathic pain • Abnormal cardiac rhythms • Depression • Seizures Patent Status: Patent issued and pending Inventors: George R. Kracke, Yulia Sevryugina and M. Frederick Hawthorne Contact: Charlie Hanford, or 573-882-0477

NOVEL DYSTROPHIN MEMBRANE-BINDING DOMAINS (MBDS) Duchenne muscular dystrophy is a lethal muscle-wasting disease caused by mutations in the dystrophin gene. Dystrophin plays an important role in maintaining the integrity of the sarcolemma (muscle cell membrane). Lack of functional dystrophin leads to membrane leakage and disruption. Damage of the muscle membrane initiates chain reaction that eventually ends up

Potential Areas of Application: • Muscular Dystrophy • Duchenne Muscular Dystrophy Patent Status: Patent pending Inventors: Dongsheng Duan, Yi Lai, Junling Zhao and Yongping Yue Contact: Charlie Hanford, or 573-882-0477

OPTICAL POLARIZATION TRACTOGRAPHY: A NEW HIGH-RESOLUTION IMAGING TECHNOLOGY FOR EARLY DETECTION OF DISEASED TISSUES The current invention from MU uses non-destructive optical polarization tractography (OPT) to generate high-resolution, 3-D images of tissue fiber organization from cellular to organ levels. This technology can be used in clinical diagnosis to identify various abnormal and diseased tissues of various types, such as skeletal muscle, nerve fiber, dental tissue, cartilage, heart muscle and blood vessel. The technology is portable, low-cost to implement and can identify fiber disorganization/ damage in skeletal and cardiac muscle for early detection of heart diseases and other tissue fiber abnormalities. Current tissue imaging technologies, such as optical coherence tomography (OCT), cannot provide accurate images of the fiber architecture in fibrous tissues. Changes to the fibrous structure of various biological tissues generally occur under disease or pathological conditions, such as the onset and progression of heart failure or atherosclerosis. Cellular level fiber architecture changes are excellent biomarkers for early disease diagnosis and for monitoring disease progression and response to therapy. Unfortunately, current tissue imaging technologies do not have the resolution to detect

fiber organization changes at the cellular level. The current invention of OPT technology represents a revolutionary advancement in tissue imaging technology that can improve our understanding of pathogenesis, monitoring of progression of disease conditions and assist in treatment modalities by offering unique imaging capabilities, such as detailed 3-D tissue visualization with cellular resolution.


in muscle necrosis, fibrosis, inflammation and loss of muscle function. Traditionally, dystrophin is divided into four functional domains: N-terminus (NT), the mid-rod domain, the cysteine-rich (CR) domain and C-terminus (CT). The mid-rod domain consists of 24 spectrin-like repeats (R) and four hinge regions (H). Dystrophin is a subsarcolemmal protein. It maintains sarcolemmal integrity by providing a mechanical and signaling link between the actin cytoskeleton and the extracellular matrix (ECM). A critical aspect of this link is the direct interaction of dystrophin with the muscle cell membrane. The prevailing theory suggests that the CR domain anchors dystrophin to the sarcolemma through direct binding to the transmembrane protein β-dystroglycan. Β-dystroglycan then connects with the ECM. In this model, the CR domain is the sole component of dystrophin that can bind to the muscle membrane. Membrane binding is essential for dystrophin to maintain membrane integrity. In this work, novel synthetic dystrophins were developed that bound dystrophin independently of the CR domain. This has important therapeutic implications, potentially allowing for new novel synthetic dystrophins with superior function for the treatment of muscular dystrophy.

Potential Areas of Application: • An effective, low-cost, portable imaging tool to reveal tissue fiber abnormalities in skeletal muscles, nerve fibers, dental tissue, cartilage, heart muscles and blood vessels • Provide more detailed images of complicated tissues by offering 3-D capabilities, high imaging speed and cellular-level spatial resolution Patent Status: Patent pending Inventors: Gang Yao, Dongsheng Duan and Yuanbo Wang Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

OSTEOARTHRITIS BIOMARKER PANEL Osteoarthritis (OA) is the most common form of arthritis in humans and affects almost 10 percent of the population in the U.S. and Europe. Currently, there is no commercially available assay(s) for diagnosis, staging or monitoring of the disease. The most common clinical approach uses physical examination and radiographic (X-ray) findings for evaluation of subjects that are exhibiting symptoms. This approach results in osteoarthritis being definitively diagnosed after it has significantly impaired function and quality of life. At this point, therapeutic options may be less efficacious. The current invention developed by MU researchers is a human biomarker panel that may be useful for determining presence, severity and extent of OA. The panel uses readily available fluid samples, which are analyzed for specific biomarkers associated with OA. By comparing the levels of biomarkers in the fluid samples to normal values, the panels will allow for diagnosis, screening, staging and judging of the effectiveness of treatments with high certainty. Potential Area of Application: • In-clinic tests for diagnosis, screening, staging, treatment monitoring and prognostication of OA Patent Status: Patents issued and pending Inventors: James L. Cook, Aaron M. Stoker, Keiichi Kuroki, Bridget Garner, Cristi Reeves Cook, Richard Evans, Brandon Roller and Prakash Jayabalan Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553


OSTEOCHONDRAL ALLOGRAFTS FOR THE ANKLE The current invention from MU is directed to the development of viable osteochondral allografts for functional biologic ankle joint replacement in patients with severe ankle trauma and/or arthritis. The invention is a surgical instrumentation system for creating allograft implants and recipient graft sites with a precise fit for joint movement. This technology should replace current standard-of-care salvage procedures for ankle injuries and arthritis, such as ankle fusion, to return patients to pain-free, highly functional activity. The ankle joint is the most commonly injured joint in the body. Ankle fractures occur in cases of high-energy trauma, such as motor vehicle, extreme sports and cycling accidents, and those of low-energy trauma, such as falls, athletic events and other repetitive impact activities. Patients with ankle arthritis are usually younger than those with knee or hip osteoarthritis. The longer projected life span, combined with the substantial decrease in health-related quality of life, underscores the profound effect that ankle trauma and osteoarthritis have on patient disability. Total ankle replacements using metal and plastic implants have not resulted in consistently successful outcomes, and the alternatives of ankle fusion or amputation are not functional alternatives. Given the available options, the current invention provides a new and attractive system for treating ankle arthritis and traumatic injury. Potential Areas of Application: • Demonstrates novel method to address ankle trauma and arthritis with a higher predicted probability of surgical success for functional outcomes Patent Status: Under evaluation Inventors: Ferris M. Pfeiffer, James L. Cook and James P. Stannard Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

SHELL CUTTER INSTRUMENTATION FOR PATIENT-SPECIFIC OSTEOCHONDRAL ALLOGRAFTS The current invention developed at MU presents a system to create a recipient site in a patient’s joint and matching osteochondral allograft (OCA) of a shape, contour and thickness specific to the joint for allograft transplantation. This technology uses surgical guides made from medical-grade materials that contours to the patient’s joint surface(s) to create an anatomy-specific recipient site, followed by instrumentation of the donor tissue to create a precisely matched OCA for transplantation. Most current OCA instrumentation systems do not allow for patient-specific implants, but MU’s shell cutter system allows the donor tissue to be created in an anatomy-specific shape, precisely matched to the recipient site for more complete joint restoration. MU’s technology presents a more accurate joint geometry and improved function compared to OCA instrumentation systems that are not patient-specific. OCA transplantation is a proven and growing orthopedic procedure for patients needing restoration of the 36

articular surfaces of joints. Organ donor tissues from accredited tissue banks are used to create allografts for transplantation into recipient site(s) in patients. MU’s shell cutter system improves this method of treatment. Potential Areas of Application: • Treatment of damaged joint surfaces in the knee, hip, ankle, shoulder and elbow of human and veterinary patients • Alternative to partial or total joint arthroplasty options Patent Status: Patents pending Inventors: James L. Cook, Ferris M. Pfeiffer and James P. Stannard Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

STEM CELLS SYNERGIZE WITH IMMUNE MODULATION FOR TREATMENT OF TYPE I DIABETES MU researchers have developed a novel method to treat type I diabetes (T1D). While insulin is necessary for survival, it does not treat the disease. The inventors have previously shown that an Ig-GAD2 regimen given to non-obese diabetic mice prevented disease progression. By accompanying their previous methods with the transfer of bone marrow cells from healthy donors, researchers were able to induce immune modulation of islet inflammation, repair islet vasculature and sustain regeneration and function of insulin-producing cells, leading to the reversal of overt T1D. While the bone marrow cells gave rise to the endothelial cells in the pancreas, the new β-cells were of host origin. Also, the treatment ablated insulin-resistance associated with the onset of T1D. Thus, overcoming T1D requires both immune modulation and repair of the vascular niche to preserve the newly formed β-cells. Potential Area of Application: • Type I diabetes treatment Patent Status: Patent pending Inventors: Habib Zaghouani, Renu Jain and Randal Gregg Contact: Charlie Hanford, or 573-882-0477

SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO THE RETINA MU researchers have invented a novel technology to treat retinal degenerative disorders. This approach will allow continuous delivery of therapeutic agents, such as replacement enzymes, to the retina over long periods of time after a single treatment. They are performing preclinical studies treating the late-infantile form of Neuronal Ceroid Lipofuscinosis (NCL) using a canine model they have developed. The canine model will allow assessment of safety and efficacy in using enzyme replacement, stem cell and gene therapies for this and related diseases. As a result,

The current invention from MU researchers is an FDA-approved biomaterial used for rotator cuff repair/ allograft site design as well as an improved surgery method that could increase surgery success rates.

Potential Areas of Application: • Diabetic retinopathy • Retinal degenerative disorders • Age-related macular degeneration • Neuronal Ceroid Lipofuscinosis (NCL) Patent Status: Patent pending Inventors: Martin Katz, Joan R. Coates, Christopher Tracy, Rebecca E.H. Whiting and Jacqueline Pearce Contact: Charlie Hanford, or 573-882-0477

Potential Areas of Application: • Rotator cuff surgical repair • Rotator cuff reconstruction Patent Status: Patent pending Inventors: Ferris Pfeiffer, James L. Cook and Matthew J. Smith Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553


University of MissouriKansas City

The present technology utilizes a gelatin nanoparticle to introduce both siRNA and a drug into a cell of interest. The drug is encapsulated in the nanoparticle while an antibody and the siRNA are conjugated to the surface of the nanoparticle. The present work has demonstrated an effective means for treating un-druggable cancer mutations, in particular the KRas mutation. Once the nanoparticle is taken up into the KRas cell, the siRNA drives the cancer cell to use an alternate cellular mechanism. This alternate mechanism is then treated via the encapsulated drug, which causes cell death. Potential Areas of Application: • Oncology • Non-small cell lung cancer treatment Patent Status: Patent pending Inventors: Srikar Raman and Raghu Kannan Contact: Charlie Hanford, or 573-882-0477

TOOL AND PROCESS ALIGNMENT AND SITE PREPARATION OF NOVEL ROTATOR CUFF GRAFTS Rotator cuff tears are one of the most common shoulder joint injuries. This injury occurs when one or more tendons that connect shoulder muscles to bone become torn, leading to pain and dysfunction of the arm. Between 1998 and 2004, more than 5 million physician visits were associated with rotator cuff problems. There are multiple options to help repair a rotator cuff injury, depending on the severity. Smaller tears can be managed non-operatively; however, larger injuries require surgical reconstruction to restore arm function. In the U.S. alone, there are more than 50,000 surgeries completed annually. Tissue allografts are a common surgical technique used to repair tendon damage and fully restore function to the shoulder. Without proper site preparation for the allograft, failure rates of surgery can range from 20 to 70 percent leading to increased discomfort and additional surgeries later in life.


this new technology has the potential to provide an economic solution to treat retinal degenerative disorders with lower risk.

BIOCOMPATIBLE BONE CEMENT Currently available commercial bone cements are composed of polymethyl methacrylates and have several notable disadvantages, including toxicity, lack of bioactivity, volumetric shrinkage, tissue necrosis and the generation of heat upon polymerization. Due to the high temperatures produced during polymerization, antibiotic treatment with bone cement is limited. The current invention developed by UMKC researchers is a chemically initiated cement that is composed primarily of a monomer that has already proved effective in commercial dental composites. Our extensive testing of this new cement has found that this system is biocompatible, has a peak exotherm that is below 45 degrees C, has low shrinkage and contains excellent mechanical properties. This system provides a biocompatible alternative bone cement while maintaining good mechanical properties. Potential Areas of Application: • Orthopedics and dental - Use as a lower toxicity bone cement - Use in kyphoplasty or other procedures - Use in revision surgeries of implants with bone loss Patent Status: Patent issued Inventors: Kathleen Kilway, Lynda Bonewald and Thomas Schuman Contact: Eric Anderson, or 816-235-5091

DENTAL ETCHING GEL WITH COLLAGEN-STABILIZING FUNCTIONALITY Current dental restorations may use a composite or an amalgam material. For various reasons, such as cosmetic preference, one may choose to utilize a composite material in a dental restoration. However, certain current composite tooth restorations exhibit a shortened lifespan compared to a tooth restoration performed with a traditional amalgam filling. This shortened lifespan may be due to a breakdown of at least a portion of the den37

tin collagen that interfaces with the composite material. Therefore, there is a need for compositions that can be used in a dental restoration process, such as a composite or ceramic dental restoration that increase the stability of dentin collagen. One countermeasure to the issue is to incorporate a collagen cross-linker in the bonding procedure to stabilize dentin collagen against these degradations, and consequently, elongate the lifetime of restoration. Grape seed extract (GSE) is extremely valuable because it is non-toxic, and affords full protection of dentin collagen in a clinically acceptable 30 seconds. This use of GSE is thus far the only collagen cross-linker that exhibits un-compromised efficacy in acid. Potential Area of Application: • Dental restorations Patent Status: Patent pending Inventors: Yong Wang and Yi Liu Contact: Eric Anderson, or 816-235-5091

LIGHT-ACTIVATED INSULIN DEPOT Worldwide there are tens of millions of insulin dependent diabetics. These patients must either subject themselves to multiple daily injections of insulin or have an insulin pump deliver the insulin to their abdomen by cannula. Insulin pumps can be inconvenient and carry the risk of infection, while daily injections are burdensome and prone to patient non-compliance and poor blood sugar control. Poorly controlled blood sugar is known to cause a wide range of serious short-term and long-term health problems in diabetic patients. The current invention developed by UMKC researchers is a light activated insulin depot, in which a single injection under (or within) the skin contains potentially hundreds of injections worth of insulin. The insulin is then released as needed by subjecting the skin above the injection to a specific wavelength of light. The depot material has three main elements: an insoluble polymer material, insulin and a light cleavable linker to join the polymer and insulin. The polymer keeps the insulin physically near the site of injection, while the light cleavable linker then joins insulin to this polymer. When transdermal irradiation occurs via pulses of LED light, the bond breaks, releasing a controlled amount of insulin that is proportional to the intensity and duration of the irradiation. Potential Areas of Application: • Weekly or monthly delivery of insulin via depot injection • Use in conjunction with a continuous glucose monitor to provide constant blood sugar levels Patent Status: Patent pending Inventors: Simon Friedman, Piysh K. Jain, Dipu Karunakaran and Bhagyesh R. Sarode Contact: Melanie Roberts, or 816-235-5090 or

38 38

SOLUBILITY-ENABLING COATING FOR PHARMACEUTICALS UMKC researchers have developed a process to increase solubility of various pharmaceuticals by applying a coating that utilizes sodium acetate during nanoencapsulation of pharmaceuticals for improved physiochemical and biological properties. Sodium acetate is an FDA-approved substance for human use. The nanoparticles exhibited higher encapsulation efficiency (~90%) of water soluble drugs such as tenofovir. Potential Areas of Application: • Improved delivery and solubility of poorly soluble drugs • Prevents the degradation of protein based drugs • Protects against moisture, oxidation, light and microbial growth • Increases the shelf-life of the pharmaceutical • Control of release rate of pharmaceutical Patent Status: Patent pending Inventors: Bi Botti Youan and Albert Ngo Contact: Eric Anderson, or 816-235-5091

University of Missouri St. Louis DETECTING AND TREATING TB USING LIPASE INHIBITORS Tuberculosis continues to kill nearly 1.5 million people annually, making it the most deadly infectious disease worldwide – especially in Sub-Saharan Africa, Russia and Eastern Europe. With the recent emergence of multiple drug-resistant strains, the increasing number of HIV cases, as well as the disappointing failures of the Gates-backed TB vaccine (MV85A), the need for novel therapeutic approaches is more pressing than ever. While there is growing awareness of the need for diagnosing tuberculosis and for drugs that can treat the disease, many of the promising new molecules in development are either repurposed drug compounds or new derivatives of known anti-mycobacterial drugs; none are reported to target intracellular lipid metabolism. Researchers at UMSL, in collaboration with scientists at the National Center for Scientific Research in France, have developed powerful lipase inhibitors from enolphosphonate and enolphosphate families that show promising anti-tuberculosis activities on M. tb with no cytotoxicity effects. Additionally, fluorescently labeled compounds were shown to easily identify mycobacterial proteins that react with the inhibitors. Selective inhibition of lipolytic enzymes (both extracellular and intracellular) from M. tb by this new class of enolphosphonates may be used to develop more selective antimicrobial agents and, more specifically, anti-mycobacterial compounds.

NOVEL BIS-AMINO ACID-BASED COMPOUNDS TO RECOVER OR ENHANCE EFFICACY OF EXISTING ANTIMICROBIALS Antibiotic resistance has become a major health crisis. Bacteria have developed resistance to most of the known antibiotics, and the rate of discovery of new antibiotics has decreased dramatically in recent years. Patients who suffer from multidrug resistant (MDR) bacteria have few treatment options.

UMSL researchers have found that novel bis-amino acid-based compounds can be used as antimicrobials or used to recover or enhance efficacy of existing antimicrobials. These compounds have been tested against two Escherichia coli strains and an Staphylococcus aureus strain and were found to reverse antimicrobial resistance activity by up to 16-fold with minimum toxicity in mammalian cells.


Potential Areas of Application: • Research tool • Diagnostics • Therapeutic Patent Status: Patent pending Inventors: Christopher Spilling, Ben Martin, Stephane Canaan and Jean-Francois Cavalier Contact: Craig Weilbaecher, or 314-516-4248

Potential Areas of Application: • Therapeutic against MDR bacteria or “superbugs” • Membrane-active antimicrobials • Adjuvant antibiotics Patent Status: Patent pending Inventors: George Gokel, Joseph Meisel and Mohit Patel Contact: Craig Weilbaecher, or 314-516-4248

The Office of Undergraduate Research

At the University of Missouri

The MU Office of Undergraduate Research provides funding and professional development opportunities for undergraduates across academic disciplines at MU. Undergraduates learn from their research experiences to prepare themselves for graduate degrees and R&D careers.

Office of Undergraduate Research 150 Bond Life Sciences Center University of Missouri Columbia, MO 65211

The public is invited to our Spring Undergraduate Research and Creative Achievements Forum on Tuesday, April 18, 2017, in the Bond Life Sciences Center to view student project posters and talk with the young researchers.



The MU Coulter Program utilizes industry best practices to accelerate the translation of biomedical innovations into products that improve patient care. By providing funding to multi-disciplinary teams for research needed to validate their envisioned product concept, the Coulter Program bridges the gap between basic research and professional investment. In addition to delivering practical solutions to important medical problems, the MU Coulter Program leads to new knowledge generation, economic development and new research collaborations.

FUNDING + Expert Feedback (Academic, Industry, Investor)

Specialized Workshops Post-award Project Management Regulatory Consulting Support Reimbursement Consulting Support Marketing Consulting Support Introductions to Industry Partners & Investors



Annual Boot Camp




Picking up Speed Elemental Enzymes, a growing University of Missouri startup company, provides ultra-stable proteins that speed up chemical reactions. Enzymes are widely used in food processing and manufacturing, because they use little energy, are non-toxic and are extremely efficient. Unfortunately, enzymes also pose challenges because they are commonly expensive to produce and typically break down extremely quickly in harsh conditions.

The proprietary and patented Elemental Enzymes technology allows enzymes to operate under higher temperatures and last longer in harsh environments or industrial processes - opening marketplaces where enzymes were previously not a viable or commercially consistent option.

In 2008, MU postdoctoral investigator Brian Thompson and Dr. George Stewart, a professor in the department of Veterinary Pathobiology, were researching bacterial structures when they discovered bacteria which would produce enhanced enzymes. These enhanced enzymes were easily harvested and lasted much longer than traditionallyproduced enzymes. This discovery is now the foundation of the technology for Elemental Enzymes, which produces ultra-stable enzymes at lower costs.

Elemental Enzymes has a number of exciting technologies that can be utilized in various agriculture market segments. The company maintains research labs at the MU Life Sciences Business Incubator and recently added an R&D facility in St. Louis, Mo. In 2015, leaders announced a cross-licensing agreement with Bayer Crop Science to further its research on crop productivity.

RESEARCH REACTOR CENTER Saving Lives in the Fight Against Cancer A New Breakthrough In Our Core Mission... MURR’s core mission is research - Research that brings technological breakthroughs to the forefront and cutting edge medical treatments to patients around the world. For example, Lutathera® is an amazing new cancer treatment from Advanced Accelerator Applications (AAA). Lutathera is currently under fast-track FDA review after successful clinical trials. With accelerated review underway, cancer patients suffering from gastro entero pancreatic neuroendocrine tumors (GEP-NETs) will have great hope in the face of this otherwise fatal disease. MURR proudly provided the lutetium-177 (Lu-177) active ingredient throughout clinical trials and is now positioned to supply the entire U.S. need of Lu-177 for this drug. Until the drug is approved, patients may seek treatment under a compassionate care approval. See for more info.

Additional Exciting Projects... Radiopharmaceuticals currently on the market, as well as those in various research stages, need a reliable supply of active ingredients, and MURR meets those needs on a weekly basis. Here are a few of our current isotope projects: Mo-99—Molybdenum-99 is the parent isotope of Technetium-99m (Tc-99m), the most widely used radio-pharmaceutical in the world, which currently has no American supply. MURR is currently working with three unique Mo-99 projects designed to ensure that the 16 million U.S. patients annually get the diagnostics they need. I-131— Iodine-131 is at the heart of the 2nd-most commonly used radiopharmaceutical and has no U.S supply. MURR is commissioning a new facility to ensure thyroid cancer patients receive the treatment they need.

Some of our Successes...

MURR’s current projects are building upon a well-established track record of accomplishments. Quadramet® and TheraSphere® are both examples of collaborations with private industry that brought new cancer treatments to market. MURR continues to supply active ingredients for each of these radiopharmaceuticals on a weekly basis. Essential Isotopes LLC is an MU partnership featuring a 16 MeV cyclotron, located at MURR, that supplies isotopes in the mornings region-wide for patients needing PET imaging, and throughout the day to support various research initiatives.

How can we help you? Contact us today! @MURRmatters

Web: Email: Tel: 573-882-4211


LIFE SCIENCES ABSTRACTS UNIVERSITY OF MISSOURI 44 Air Pulse Device for Laryngeal Adductor Reflex Evaluation 44 Crop Nitrogen Decisions From Aerial Images 44 Crop Resistance to Nematodes 45 Diagnostic Test Kit for Swallowing Disorders in Animals 45 Engineered Minichromosomes in Plants 45 Field Management Tool for Agrochemical Application 45 Increased Tocochromanol (Vitamin E) Content in Leaves and Seeds of Soybeans 46 Increasing Plant Oil Content by Altering Negative Regulators of Acetyl-CoA Carboxylase 46 K9 Observation Kennel 46 Medium Supplement to Increase the Efficiency of Oocyte Maturation and Embryo Culture in Vitro 47 Nanostructured Carbon Biocatalyst with a Variety of Applications 47 Novel Assay for Detecting Multiple Shiga Toxin-Producing Escherichia Coli and Salmonella for New USDA Standards 47 PCR-Based Assay to Identify Bacteria Resistant to Last-Resort Antibiotics 48 Q Fever Peptide Mimetic Vaccine 48 Semen Extender Additive for Artificial Insemination, In Vitro Fertilization and Embryo Transfer 48 Superior Method to Artificially Activate Pig Embryos to Generate Cloned Pigs 49 Tissue-Specific Soybean Promoters 49 Ultra-Rapid Cooling Method for Cell Cryopreservation 49 Wireless Force-Measuring System for Detecting Lameness and Analyzing Gaits in Animals

MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY 50 Single Cell Fiber Optic Microprobes 50 MRI/MNR Calibration Device

UNIVERSITY OF MISSOURI - KANSAS CITY 50 Enhancing Fatty Acid Amide Hydrolase Activity

UNIVERSITY OF MISSOURI - ST. LOUIS 50 Immobilized Chelators for Removal of Metals at Varying pH



This invention developed at MU presents a unique technology to objectively measure the laryngeal adductor reflex (LAR). The technology may be used to quantify and evaluate the LAR in all types of mammals ranging from laboratory rodents to horses to humans. This system uses air pulses, which may be delivered to the vocal cords at varying pressures and durations, and has many advantages. The integrated control system allows numerous LAR responses to be obtained with minimal operator input and is designed to interface with commercially available endoscopes. This technology will improve the diagnosis and treatment of mammals affected with maladies that exhibit LAR abnormalities such as dysphagia and neurological disorders. Current systems only measure the threshold pressure that elicited the LAR, whereas this technology is capable of measuring the response in its entirety, allowing more accurate diagnosis and treatment. The LAR is a brief, bilateral and involuntary closure of the vocal folds that prevents foreign material from entering the airway. One of the most clinically significant applications of the LAR is its use in laryngopharyngeal sensory discrimination testing. Potential Areas of Application: • Diagnosis of dysphagia in mammals • Early screening for such neurological disorders as ALS and Parkinson’s disease • Prediction of vocal cord dysfunction and pediatric apneas Patent Status: Patent pending Inventors: Teresa Lever and Cameron Hinkel Contacts: Samuel E. Bish, or 573- 882-5016; Nancy Parker, or 573-884-3553

CROP NITROGEN DECISIONS FROM AERIAL IMAGES This invention developed by MU researchers is a technology that will predict crop yield loss due to nitrogen deficiency at mid-season, and the amount and placement of fertilizer to meet crop needs. This revolutionary technology allows corn, wheat, rice and potato producers to assess economic loss due to nitrogen deficiency and make sound business decisions about the profitability of mid-season fertilizer application. This aerial imagery can also be used to create fertilizer-control files, automating the process of putting the right fertilizer rate in the right place. Crop production is increasingly becoming dependent on technology to maximize crop yield at minimum cost and labor. Crop yield loss can occur for various reasons, one of which is nitrogen deficiency caused by wet weather. Farmers need sound information on the severity of this problem to guide decisions on whether to invest in more fertilizer. Nitrogen loss is patchy and imagery can guide producers to apply higher fertilizer rates in the areas of the field where more was lost. 44

Potential Areas of Application: • Predict yield loss of crops including corn, wheat, rice and potato • Detect areas for mid-season fertilizer application • Analyze economic outcome of mid-season fertilizer application • Guide variable-rate, mid-season fertilizer application Patent Status: Patents issued Inventors: Peter C Scharf and Vicky C. Hubbard Contacts: Samuel E. Bish, or 573- 882-5016; Nancy Parker, or 573-884-3553

CROP RESISTANCE TO NEMATODES Parasitic nematodes that attack plant roots are estimated to cause an annual worldwide crop damage of over $100 billion. For soybeans, the most important pathogen is the nematode Heterodera glycines, which causes an annual loss in the U.S. of more than 120 million bushels valued at over $1.2 billion. Other Heterodera species can cause significant damage to corn, while potato nematodes of the Globodera genus can result in up to 60 percent reduction in potato yield. Crops resistant to nematodes are, therefore, of great economic interest. The current invention developed by MU researchers is a genetic approach to make plants resistant to infestation from cyst nematodes attacking soybeans, corn and potatoes. The nematodes secrete effector proteins connect with the plant’s root cells, and plants lacking the receptors that these effector proteins interact with have increased nematode resistance. Disruption of the plant receptors did not result in obvious changes to root growth in the plant and can be used to develop a novel management tactic to reduce cyst nematode parasitism of crop plants. Potential Areas of Application: • Nematode-resistant corn, soybean and potato crops Patent Status: Patents pending Inventors: Melissa Goellner Mitchum, Amy Replogle, Jianying Wang, Xiaohong Wang, Shiyan Chen, Ping Lang, Eric L. Davis, Thomas J. Baum and Richard Hussey Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

DIAGNOSTIC TEST KIT FOR SWALLOWING DISORDERS IN ANIMALS The current invention, developed at the University of Missouri, presents a unique technology for the diagnosis and treatment of dysphagia in companion animals. This technology consists of specially formulated recipes that mask the aversive taste and odor of oral contrast agents required to conduct effective videofluoroscopic swallowing studies. These ready-to-use kits contain savory recipes with an oral contrast agent, but are readily consumed by companion animals in a low-stress, self-feeding environment. The animals perform normal, not forced, swallowing with simultaneous and effective visualization of their digestive tracts. These kits will

Potential Areas of Application: • Videofluoroscopic swallowing studies in dogs and other companion animals • Radiographic studies involving the digestive tract of companion animals, including quantifying the effect of new drug candidates on swallowing function • Diagnosis and treatment of dysphagia Patent Status: Under evaluation Inventor: Teresa E. Lever Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

ENGINEERED MINICHROMOSOMES IN PLANTS The use of genetically modified crops is constantly finding new areas of application, including the production of compounds with therapeutic value. Current technology for producing transgenic crops relies on random integrations that can have variable expression and could potentially disrupt the endogenous genes. Also, combining multiple transgenes requires a lengthy crossing scheme and can bring along linked genes from one variety into another. The current invention developed by MU researchers allows continued addition of transgenes as the need arises using engineered plant minichromosomes. Artificial chromosome platforms were produced by telomere-mediated truncation while simultaneously adding DNA sequences that will permit amendments to the chromosome indefinitely. These minichromosomes can be used as a vector for efficient stacking of multiple genes for insect, bacterial and fungal resistances together with herbicide tolerance and crop quality traits unlinked to endogenous genes in a circumstance that would foster faithful expression. Potential Area of Application: • Genetically engineered crops Patent Status: Patents issued and pending Inventors: James A. Birchler and Weichang Yu Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553



improve the diagnosis and treatment of animals suffering from dysphagia and other swallowing abnormalities that affect their quality of life. Dysphagia diagnosis and treatment in humans and companion animals is difficult because of how the contrast media and observation influences natural swallowing functions. Swallowing function is markedly different during voluntary swallowing compared with restraint and force-feeding conditions. Higher stress force feeding is often required, especially with animals, because of the repulsive taste, texture and odor of the oral contrast media. The current technology is ready-to-use, prepackaged savory recipes containing oral-contrast media that allow for natural and objective diagnosis and treatment of dysphagia in dogs.

With increasing costs of inputs and rising concerns over off-target contamination, effective management tools are required for the application of fertilizers and other agrochemicals to maximize efficiency and reduce nutrient runoff. For example, enhanced efficiency fertilizer, such as slow-release fertilizers, can reduce the risks of nutrient loss compared to conventional fertilizers, but at a higher cost. One strategy to overcome in-field differences in potential nutrient loss is to apply the enhanced efficiency fertilizer to the high risk nutrient loss areas of a field while applying conventional fertilizer to the low-risk areas. An invention that would assist farmers to identify and map the low- and high-risk areas of a field and then facilitate the application of multiple agrochemicals in the field based on those identified areas would help to increase profits and lower environmental losses. The current invention developed by MU researchers is a software tool and algorithm to determine and apply different types and amounts of agrochemical sources to predetermined zones within a field. The tool takes into account spatial differences in intrinsic soil properties that affect agrochemical efficiency, including soil drainage and water content. It allows for storage of historical data so that better management practices can be achieved, increasing productivity while reducing negative environmental impact. Potential Areas of Application: • Maps zones vulnerable to agrochemical loss or reduced efficiency based on spatial differences in soil and environmental properties • Field management and control of variable source agrochemical application • Establishes geographically referenced application history Patent Status: Patents issued and pending Inventors: Peter P. Motavalli and Kelly A. Nelson Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

INCREASED TOCOCHROMANOL (VITAMIN E) CONTENT IN LEAVES AND SEEDS OF SOYBEANS Tocochromanols, or Vitamin E, is a group of plantderived, lipid-soluble compounds with beneficial antioxidant activities. Because humans and animals cannot product Vitamin E, it has to be supplied in the daily cited. Green leafy vegetables contain some of the highest levels of Vitamin E. There is also a growing body of evidence that Vitamin E may counteract the onset and progression of cancer and cardiovascular diseases. The global vitamin market is forecasted to reach $3.2 billion by the year 2017. Vitamin E represents the largest segment. MU researchers have increased the level of tocochromanols by 27-fold in soybean seed, mainly in the form of γ and β-tocopherols. This coupled with the benefits from soybean isoflavones in men and women, make the addition of natural Vitamin E to soybeans a unique combination. Although not yet field tested, these high vitamin E lines also showed increased tolerance to the class of HPPD herbicides. 45

Potential Areas of Application: • Soybeans as a source of natural Vitamin E • Source of soybean seeds as an edible snack with enhanced Vitamin E • Source of natural vitamin E in soybean based cosmeceuticals • Source for the animal feeds market and pet foods • Non-GMO source of herbicide resistance Patent Status: Patent pending Inventors: Gary Stacey and Minviluz (Bing) Stacey Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

INCREASING PLANT OIL CONTENT BY ALTERING NEGATIVE REGULATORS OF ACETYL-COA CARBOXYLASE The current invention provides a means to increase the fatty acid, and ultimately the triacylglycerol production, in plants and algae. Such an approach involves altering the activity levels of the committed step for de novo fatty acid biosynthesis involving acetyl-CoA carboxylase (ACCase). A newly discovered gene family of negative regulators, called BADC proteins, bind to the heteromeric ACCase found in algae and most plants and reduces activity biochemically. By down-regulating these genes through biotechnology approaches, the activity of ACCase is enhanced, resulting in greater flux through de novo fatty acid biosynthesis, thereby leading to increased oil content in plant cells. Potential Area of Application: • Increase the leaf or seed oil content in major row crops Patent Status: Patent pending Inventors: Jay Thelen and Matthew Salie Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

K9 OBSERVATION KENNEL Radiographic examinations are one of the most common diagnostic tools in veterinary practices and animal research labs. The problem with many of these examinations is that an animal has to remain relatively still to obtain quality radiographic images. Likewise, if a videofluoroscopic test is required, the animal has to be restrained to complete the test. There are various methods employed to control an animal, including manual restraints, sedation, short-acting anesthesia and human intervention. However, each of these methods prevents testing of typical animal behaviors and results in anxiety in the animal and an accurate diagnosis. In addition, the use of restraint methods results in increased radiation exposure to technicians. MU’s invention is a translucent and radiolucent kennel designed for a safe and efficient means for conducting behavioral and radiographic examinations on animals. The kennel is designed to permit a variety of assessments in several anatomical planes while providing a comfortable testing environment for animals and technicians. Radiographic examinations can be conducted without restraints while permitting quality spot images as well as accurate videofluoroscopic tests. 46

Potential Areas of Application: • Veterinary practices that require radiographic and behavioral tests • Animal researchers who use radiographic and behavioral tests • Veterinary school teaching • Pharmaceutical companies completing animal trials Patent Status: Patent issued Inventors: Teresa E. Lever, Joan R. Coates, Mitchell Allen and Laila Al-Khashti Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

MEDIUM SUPPLEMENT TO INCREASE THE EFFICIENCY OF OOCYTE MATURATION AND EMBRYO CULTURE IN VITRO This MU invention is a chemically defined medium supplement that consists of a synergistic combination of growth factors. The supplement provides a greater number of high-quality in vitro matured (IVM) oocytes and in vitro cultured (IVC) embryos than other protocols currently on the market and eliminates drawbacks of using undefined conditions. Oocyte IVM and embryo IVC have wide applications in basic research, human medicine and agricultural production. However, in many species the success and the quality of in vitro produced oocytes and embryos is often very low when compared to in vivo counterparts. Studies indicated that certain important components are still missing in the current culture system, which results in compromised oocyte and embryo quality. This invention provides a defined oocyte maturation and embryo culture environment that can improve oocyte maturation and subsequent in vitro production of embryos. Potential Areas of Application: • Produce more competent IVM oocytes from livestock that can be used to produce a greater number of competent embryos for transfer • Improve efficiency of human oocyte IVM and help broaden the use of IVM for fertility preservation • Improve the efficiency of IVM of oocytes from rare and endangered species for wildlife conservation Patent Status: Patent pending Inventors: Ye Yuan, Lee D. Spate, Randall S. Prather and R. Michael Roberts Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

NANOSTRUCTURED CARBON BIOCATALYST WITH A VARIETY OF APPLICATIONS The current invention developed by MU researchers is a nanostructured, carbon-based biocatalyst for remediation of unwanted organic substances such as pesticides and other environmental pollutants. Enzymes capable of detoxifying organic chemicals are tethered to functionalized carbon-particles, which serve as delivery

Potential Areas of Application: • Soil and water cleanup • Drug-delivery systems • Biodefense applications • Fuel cell development • Biofuel production Patent Status: Patents issued Inventors: Chung-Ho Lin and Brian M. Thompson Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

NOVEL ASSAY FOR DETECTING MULTIPLE SHIGA TOXIN-PRODUCING ESCHERICHIA COLI AND SALMONELLA FOR NEW USDA STANDARDS The current invention from MU is a novel assay to detect seven Shiga Toxin-Producing Escherichia Coli (STEC) serogroups, seven Shiga toxin genes and salmonella in non-intact beef. Specifically, the assay involves only two multiplex, melt-curve, real-time PCR reactions for detecting 15 target genes. This assay includes a specifically designed internal amplification control (IAC) for each reaction that ensures robustness and minimizes false negative results. Specific primers were designed and uniquely optimized to detect each individual STEC serogroup without any cross-reactivity to other STEC serogroups, or salmonella strains. Unlike commercially available methods, this assay does not rely on fluorescent labelled probes or magnetic beads to detect and discriminate among targeted STEC serogroups. Instead, it relies on unique melting temperatures of the specific DNA sequences from each serogroup, which will reduce assay costs and extend test reagent shelf life. The assay has been tested on a variety of food products such as ground beef, beef trimmings, juices, produce and poultry products, has a shortened enrichment period (10-12 hours or less) and obtains a highly sensitive detection level while being simple to perform. There is a current lack of rapid, accurate and sensitive methods for detecting STEC strains that cause serious illnesses, including a fatal hemolytic uremic syndrome (kidney failure). Moreover, commercially available assays for the detection of STEC serogroups use fluorescent probes or antibody-based approaches, which are more expensive and have shorter storage lives. This method has modest requirements and can be compatible with other real-time PCR, or automated diagnostics

platform, making it a convenient and most cost effective method for the detection of STEC and Salmonella.


vehicles, stabilizers and chemo-attractants. The system is easy to produce and modify and can be tailored to the detoxification of a variety of chemicals. This invention provides a new and improved series of amide-functionalized ordered mesoporous carbon (AFOMC) as a vehicle and system to deliver enzymes that degrade pollutants, toxins or other unwanted organic substances. Additionally, this conjugation of bioactive enzymes onto the amide-functionalized ordered mesoporous carbon has a wide range of other commercial applications, ranging from the development of biocatalysts, biofilters, fuel cells, biofuel production, drug delivery systems other medical therapeutics and biosensors. The variety of potential applications makes this technology highly attractive.

Potential Area of Application: • Potential to become a standard assay for STEC detection in the food industry and food regulatory agencies, such as meat, produce and juice testing Patent Status: Patent pending Inventors: Azlin Mustapha and Prashant Singh Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

PCR-BASED ASSAY TO IDENTIFY BACTERIA RESISTANT TO LAST-RESORT ANTIBIOTICS The current invention is a multiplex, real-time PCR assay that detects some of the most common genes that confer resistance to extended-spectrum β-lactam and carbapenem antibiotics, which are classified as last-resort antibiotics used when no other drugs are found effective. The assay involves two multiplex melt-curve, realtime PCR reactions for detecting ten β-lactamase and carbapenemase gene families and their gene variants. Each multiplex reaction includes an internal amplification control (IAC) that is specifically designed to ensure robustness and minimize false negative results. Specific primers were designed and uniquely optimized to detect individual antibiotic resistance genes without any crossreactivity to other similar genes. Gram-negative pathogens resistant to antibiotics of last resort, such as extended spectrum β-lactams and carbapenem, may lead to serious, difficult-to-treat human infections, including urinary tract or bloodstream infections. There are only a limited number of molecular-based methods available to detect antibiotic resistance genes. Commercially available RT-PCR-based methods target a minimal number of genes and rely on fluorescent labelled probes. The present invention, on the other hand, detects a higher number of genes and uses unique melting temperatures of specifically amplified DNA sequences in the PCR reaction, enabling lower cost per sample and extended shelf life for the kit. The assay also takes less than two hours to complete making it a simple, low-cost approach for clinics and hospitals. In addition, the method is found to be compatible with multiple real-time PCR or automated diagnostic platforms. Potential Areas of Application: • Replaces time-consuming, culture-based methods of detecting last-resort antibiotic resistance • Meets U.S. Centers for Disease Control and Prevention recommendations that health care facilities use more rapid molecular methods for antibiotic resistance detection Patent Status: Patent pending Inventors: Azlin Mustapha and Prashant Singh Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553


Q FEVER PEPTIDE MIMETIC VACCINE The current invention developed by MU researchers is a Phase 1 Lipopolysaccharide (PI-LPS) targeted mimetic peptide vaccine against human Q fever. Testing has been successful in the mouse model. Q fever is a significant public health concern worldwide. This zoonotic infection is caused by Coxiella burnetii. C. burnetii, an obligate intracellular Gram-negative bacterium. It is a highly infectious and hardy bacterium that can be used in biological weapons. It is also a significant occupational hazard among veterinarians, meat-processing plant workers, sheep and dairy farmers, and researchers at facilities that house livestock. Q fever can present as an acute or chronic illness in human beings. Human symptoms vary but include nonspecific febrile illness, pneumonia, myocarditis, hepatitis, headache, and in chronic cases, can include endocarditis. Infected pregnant women may be a risk for pre-term delivery or miscarriage. Humans typically contract Q fever by aerosol inhalation of the bacteria from excreta of infected animals or contaminated soil. Q fever is a nationally notifiable disease in the United States and there is no FDA-approved vaccine. There is a vaccine used in Australia, however, it can cause adverse reactions. Thus, people must be tested and screened before vaccination, which makes it costly, time consuming and unavailable for a mass vaccination program. In the case of a bioterrorism event, a mass vaccine would be highly beneficial. Potential Areas of Application: • Safe Q fever vaccine • Immunotherapeutic strategies to control C. burnetii infections • Potential development of vaccines against other gram-negative bacteria Patent Status: Patents issued and pending Inventor: Guoquan Zhang Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

SEMEN EXTENDER ADDITIVE FOR ARTIFICIAL INSEMINATION, IN VITRO FERTILIZATION AND EMBRYO TRANSFER The current invention developed by MU researchers is a simple and inexpensive additive for semen extenders and fertilization media that improves fertilization rates after artificial insemination and in vitro fertilization. In addition, mammalian oocytes fertilized in vitro in a medium with the additive have superior developmental potential, benefiting commercial embryo transfer in livestock species and infertility treatment in humans. Artificial insemination is a technology that has aided both human and animal reproduction. However, artificial insemination does not always result in pregnancy. In the food animal production industry, an animal that does not conceive after artificial insemination results in inefficiencies and potential economic loss for the producer. In humans, the emotional toll and financial costs for couples unsuccessful in conceiving can be substantial. Both the human- and animal-assisted reproductive industries are billion dollar industries, and inventions that improve fertilization rates are highly sought after. 48

Potential Areas of Application: • Semen extender with improved sperm viability and motility • Media increasing the pregnancy rates after in vitro fertilization • Media for embryo transfer in farm animals Patent Status: Patents issued and pending Inventors: Peter Sutovsky and Young-Joo Yi Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

SUPERIOR METHOD TO ARTIFICIALLY ACTIVATE PIG EMBRYOS TO GENERATE CLONED PIGS MU researchers have developed an improved method for increasing the efficiency of cloning pigs. This method improves the efficiency of oocyte activation with unfertilized mammalian oocyte and is less time-consuming than current industry methods. This novel method activates reconstructed pig embryos. Unlike other available methods, this new approach does not fully rely on a calcium signal to activate reconstructed embryos. By chemically stimulating the downstream pathway of calcium signaling, reconstructed pig embryos can be successfully activated. In addition, the procedure is simple and user-friendly. This method may benefit the genetically-engineered pig industry by increasing the efficiency and success in generating genetically modified pigs at reduced costs. Potential Areas of Application: • Genetically-engineered pigs: - Provide human-compatible cells, tissues and organs for the treatment of human diseases, - Produce tissues for human transplant surgeries, and - Are used in medical and veterinary research. • Increased production of porcine-derived food products Patent Status: Patent pending Inventors: Kiho Lee and Randall S. Prather Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

TISSUE-SPECIFIC SOYBEAN PROMOTERS The current invention developed at the University of Missouri relates to seven promoters which provide tissue-specific expression of any gene in soybean roots and nodules. Under the control of these promoters, transgenes can be tissue-specifically expressed in xylem, phloem, cortex and epidermis of soybean root as well as cortex, infected cell and vascular bundle in soybean root nodule after inoculation with Bradyrhizobium japonicum, respectively. Our invention could be used to create transgenic soybean expressing useful traits in the appropriate tissues, eliminating any detrimental or regulatory issues that might arise from non-targeted gene expression in other tissues. A promoter is a region of DNA that initiates transcription of a particular gene. Promoters are located up-

Potential Areas of Application: • Transgenic soybean • Tissue specific gene delivery Patent Status: Under evaluation Inventors: Gary Stacey and Yaya Cui Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

ULTRA-RAPID COOLING METHOD FOR CELL CRYOPRESERVATION The current invention developed by MU researchers is an ultra-cooling method for cell cryopreservation. This novel method uses ultra-high heat transfer coefficient of thin film evaporation and vacuum regulation to create an ultra-rapid cooling method. In this method, liquid evaporates sharply using thin film evaporation and absorbs a large quantity of heat. Cryopreservation is a process where cells or whole tissues are preserved by cooling to low sub-zero temperatures. At these temperatures biological activity, including cell death, is stopped. This method of preservation is often used in semen, blood, embryo, and other tissue storage, such as corneal tissues. The ultra-cooling method created at MU demonstrates cell cryopreservation through vitrification using relatively low concentrations of cryoprotectants. Potential Areas of Application: • Cryopreservation method for animal resource centers • Cryopreservation method for biological labs sending cell samples • Cryopreservation method for biotechnology companies using cell products Patent Status: Patent pending Inventors: Hongbin (Bill) Ma, Xu Han, Fengmin Su and Hsiu-hung Chen Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

WIRELESS FORCE-MEASURING SYSTEM FOR DETECTING LAMENESS AND ANALYZING GAITS IN ANIMALS The current invention developed at MU presents a unique technology for the detection of lameness and the gait analysis of any four-legged animal. This technology is a system that uses specialized forcemeasuring sensors and electronic components for the

acquisition and wireless transmission of data. This data can be transmitted to many types of storage systems where it can then be analyzed for detection and quantification of abnormal loads (or force distributions) on the animal’s feet. This system will improve the diagnosis and treatment of animals with gait issues. Lameness detection in animals is a skill that trained experts struggle to master and that causes much disagreement, even among experts. The human eye limits what can be observed visually, and small changes in the movement of a body part due to lameness can be missed, or misinterpreted. Further, humans subjectively express how the lameness appears to them and can be biased. Current technology allows for the objective quantification of lameness and gait issues and removes subjective observations from the equation.


stream of the transcription start sites of genes and control the expression of genes. Specificity is a key feature of a promoter which determines at which time point, in which types of tissues, and at what intensity a gene is expressed. The ability to more precisely control the expression of a transgene can be very beneficial, such as reducing toxicity or insuring that the transgene is not expressed in plant tissue that is ultimately consumed, while maintaining the overall benefits of the transgene function. Despite the obvious importance, there are very limited tissue-type specific promoters reported in soybean or any major crop species.

Potential Areas of Application: • Lameness detection in quadrupeds • Gait analysis in quadrupeds • Identification of superior animals through complete analysis of stride Patent Status: Patent pending Inventors: Marco Lopes, Kevin G. Keegan, Yoshiharu Yonezawa, Hiromitchi Maki, Perngjin Frank Pai and Rod Schlotzhauer Contacts: Samuel E. Bish, or 573-882-5016; Nancy Parker, or 573-884-3553

Missouri University of Science & Technology SINGLE CELL FIBER OPTIC MICROPROBES Cellular-level research and treatments may be the way of the future for health care and medical diagnostics. Single-cell analysis technologies may ultimately prove useful in enhancing diagnostic and treatment for cellular-heterogeneous diseases such as cancer. To this end, S&T researchers invented and fabricated probes used in detecting biologically meaningful parameters, pH and temperature, in single cells, for their crucial functions in mediating a variety of cell responses to external stimuli. Researchers developed the tapered-fiber microprobes and associated instrumentation for in situ measurement of intracellular pH and temperature. Because the micro-probe gradually tapers to the bulb-shaped tip, it has improved sensitivity and accuracy and may enable the micro-probe to be inserted into and removed from a biological micro-structure with minimal damage to the micro-structure. The micro-probe’s robustness for pH and temperature sensing on cells, such as stem cells, is enabled by a unique combination of covalent bond design, dyes with higher quantum yield, photo-stability and chemical endurance, as well as inventiveness of forming ion-pair conjugates before an organic modified silica (OrMoSil) layer formation. Potential Areas of Application: • Healthcare diagnostics • Drug development • Disease detection 49

Patent Status: Patents pending Inventors: Yinfa Ma, Honglan Shi, Qingbo Yang and Hai Xiao Contacts: Keith Strassner, or 573-341-6725; John Woodson or 573-341-7544

• Control of feeding behavior of pests Patent Status: Patent pending Inventors: Peter Koulen, Kent Chapman and George John Contact: Eric Anderson, or 816-235-5091


University of Missouri St. Louis

Monitoring pH or temperature during a reaction while using MRI/NMR can be inefficient, inconvenient, and troublesome because conventional devices and techniques require the removal and or insertion of the NMR tube, thermocouple, temperature probe, etc. S&T researchers have invented in situ measuring devices, methods of making the same, and methods of using the same. The in situ measuring devices can include a capillary tube with a reference material sealed inside the tube; the capillary tube is positioned inside of a solid state or magic angle spin (MAS) rotor. A target sample can also be positioned in the interior of the solid state or MAS rotor but is sequestered from the reference material by a capillary tube wall. The in situ measuring devices can be used in solid state NMR spectroscopy to quantify one or more parameters of a target sample, such as the quantity of a sample, chemical identity of a sample or temperature of a sample. The in situ pH measuring device can measure pH of a sample, or sample environment, in a continuous fashion while observing and/or measuring the NMR spectrum of that sample. The in situ pH measuring device is capable of measuring the pH of an NMR sample in situ that is simple to implement and that encodes and affixes an imprimatur of the measured value of the pH in the NMR spectrum, affording inseparability of the pH and the NMR data and incipient integrity of same. Potential Areas of Application: • Nuclear magnetic resonance calibration • Magnetic resonance imaging diagnostic improvement Patent Status: Patents pending Inventors: Klaus Woelk, Rex E. Gerald, Ming Huang and Lingyu Chi Contacts: Keith Strassner, or 573-341-6725; John Woodson or 573-341-7544

University of Missouri Kansas City ENHANCING FATTY ACID AMIDE HYDROLASE ACTIVITY Fatty acid amide hydrolase (FAAH) is a key regulator of bioactive lipid signaling. There are several known inhibitors of FAAH. This discovery is the first to show enhancement of FAAH activity. These newly synthesized compounds stimulate the turnover of bioactive lipids in cells and organisms. These compounds are novel, highly useful tools for manipulating cell growth and biological functions in plants and animals. Potential Areas of Application: • Enhanced plant germination 50

IMMOBILIZED CHELATORS FOR REMOVAL OF METALS AT VARYING PH Metal ions cause problems in water treatment, agriculture, cleaning products, pharmaceutical applications and other areas. There currently are several commercially available chelators used to remove metal ions in various industry processes. However, current chelators only work at a specific pH or a specific pH range and are limited by the number of reactive binding sites. UMSL researchers have discovered that immobilized dithiol and citrate chelators remove soft and trivalent metals at varying pH. The chelators, immobilized on polystyrene-based resin, are superior to common ion exchange resins. They have higher binding affinities and concentrate the metal contaminants into a smaller volume for efficient recycling and disposal, providing a particularly significant advantage for large-scale processes such as paper/textiles production and water-line cleaning in thermal power plants. These chelators are useful for removing lead, cadmium, mercury, iron, aluminum, and more, across a wide range of industries from environmental remediation and water treatment to clinical settings. Potential Areas of Application: • Environmental remediation • Water treatment • Clinical settings Patent Status: Patent pending Inventors: Christopher Spilling, Wesley Harris, Surendra Dawadi and Bruce Hamper Contact: Craig Weilbaecher, or 314-516-4248


ABOUT US NVision Ag helps corn producers decide whether they need more nitrogen fertilizer for their crops — how badly, where and how much. We do this using aerial images and patented University of Missouri research to create yield-loss maps, total yield-loss estimates, and N-rate control files. NVISIONAG.COM 573-808-5396 PETER@


FOUNDER & CEO Peter Scharf, a professor of plant sciences at MU, has studied nitrogen for 30 years. He is the author of the manual Managing Nitrogen in Crop Production, published by the American Society of Agronomy.

ABOUT US SCN diagnostics provides timely, high quality plant and nematode screening services for researchers, crop advisers, farmers and others in the seed and biotech industries. While our focus is on soybeans and the soybean cyst nematode, we also conduct soil testing for other plant-parasitic nematodes. DIRECTOR & CEO Melissa Mitchum, a professor of plant sciences at MU, has 20 years of plant nematology research experience. She and her colleagues were the first to clone a soybean gene that plays an important role in nematode resistance.





How Rejuvenating! Collagen research at MU results in a better product for wound care and youthful skin. Collagen is responsible for skin’s strength, texture and elasticity. When used in a medical setting, added collagen can aid in youthful looking skin, the healing of soft tissue and the restoration of lost volume. Over time, collagen breaks down. Doctors had addressed this degradation, but the process used to alter the collagen yielded a product that was problematic for the body. In 2009 MU researchers Rebecca Rone and Dr. Sheila Grant discovered a new way to inhibit collagen degradation using nanotechnology. The collagen treated by their method is more stable and remains biocompatible— a promising factor for wound/burn care, osteoarthritis treatment and even a potential innovation for soldiers to minimize blood loss. Using their technology, Rone and Grant along with Jonathan Thompson, Anthony Harris and David Grant founded a biotechnology firm called EternoGen. The firm was the first startup company to receive competitive funding from the university’s Enterprise Investment Program. Since its inception, it has been housed in MU’s Life Science Business Incubator and opened offices in St. Louis, Mo. and Stockholm, Sweden. Eternogen has attracted more than $8.5 million in investments and is now in the commercialization phase. Dr. Sheila Grant is a professor of bioengineering at MU. She also serves as chief technology officer for EternoGen. Rebecca Rone, formerly director of MU’s Coulter Translational Partnership Program, now serves exclusively as EternoGen’s director of clinical and regulatory affairs.




Chews Like Chicken University of Missouri scientists have created the first soy product with the texture of chicken.

Meat substitutes provide essential protein without antibiotics, hormones, GMOs, trans fats and cholesterol. But many consumers are reluctant to eat substitutes, because the texture is different from meat. A soy product that tastes like chicken is nothing new, but mimicking the feel has eluded food scientists - until now. MU researchers Fu-Hung Hsieh and Harold Huff have found the recipe for success. Food Network critic Alton Brown gave their product a thumbs up: “I actually feel the product breaking down meatily in my mouth...I think these guys may be on to something.” Entrepreneur Ethan Brown of Beyond Meat quickly saw the discovery’s potential and partnered with Hsieh, Huff and MU to begin commercial production under the brand name “Beyond Meat.” With support from additional investors, including Bill Gates, the chicken-free strips are now available nationwide in Whole Foods and other familiar stores. Dr. Fu-Hung Hsieh is professor emeritus of bioengineering and food science, and Harold Huff is a senior research specialist in bioengineering. Both scientists are housed jointly in the University of Missouri’s College of Engineering and the College of Agriculture, Food and Natural Resources. Image courtesy of The Columbia Daily Tribune.

Broader Impacts Network University of Missouri • (573) 884-4334 @Mizzou_BI The Mission of the BIN is to assist researchers in the development, implementation, and evaluation of high-quality broader impacts activities for National Science Foundation proposals.



Development of the BI Plan

Networking and Identifying BI Partnerships

The BIN helps to develop strong BI plans based on individual interests and resources. We work hand in hand to identify a goal that highlights the researcher’s strengths and meets the requirements of the funding agency.

Through connections with campus and community resources and a national network of broader impacts support professionals, we work together to build a strong team to design, implement, and evaluate the BI plan.



D O Education & Training The BIN provides opportunities to learn more about broader impacts and the resources available, as well as, provides training to current and future faculty, postdoctoral research associates, and graduate students on effective BI practices.



“I really wanted to thank you for all your help, I honestly couldn’t have done it without you!”

“My program officer let me know that the broader imapcts that you worked with me on was definitely part of what made my application successful.”





“The BI proposal is superior with excellent education, societal, and evaluation components...there are no weaknesses to this component.” “The educational component is considered as a strength.” “For the BI section, the proposal is actually extremely well designed. The outreach programs and videos would be extremely useful and are the best ideas I’ve seen in such proposals.”



Biological Modeling Software Hands-Free Communication System in Mass Casualty Disaster Triage Over a Stand-Alone Wi-FI Network Knee Joint Angle Measurement for Injury Prevention Method for Objective Assessment and Training of Medical Diagnostics Skills Based on Whole-Slide Histopathology Imaging and Gaze-Tracking Quality Improvement Project Tracker Static and Moving Object Detection Using Flux Tensor With Split Gaussian Models Structure From Motion and Bundle Adjustment for Aerial Imagery and Photogrammetry Tongue Imaging for Determining Health Status Track the Trends in Complex Data With TREND

UNIVERSITY OF MISSOURI-ST. LOUIS 57 Novel Tool to Optimize Resources and Improve Efficiencies in Construction Projects


Jianlin Cheng’s lab is a world leader in creating software and algorithms that predict biological structure and function based on sequences. His protein structure prediction tool MULTICOM was recognized as one of the top three predictors at a reputed international conference in 2014, and that prediction tool forms the foundation for 3-D genome structure modeling and biological network modeling. 3-D Genome Structure modeling software, called MOGEN, can handle both inter-chromosomal and intrachromosomal interaction data to build the structure of the entire genome consisting of a number of chromosomes. Most methods in the field can only deal with intra-chromosomal interaction data to build the structure of individual chromosomes. This software has major applications in drug discovery and precision medicine. Biological Network Modeling software, called GNET, is one of the few tools that can integrate big transcriptomics data and genomics data to automatically build reliable gene regulatory networks and key transcription factors that can generate valuable hypotheses for biomedical experiments.

mander using hands-free devices and location beacons. The network can be deployed quickly and is independent of infrastructure, which may be compromised after such a disaster. It can also work with existing infrastructure that may be present to boost performance. Medical staff having their hands free to diagnose and treat patients in a mass casualty situation can greatly increase the survival rate of patients. It may also reduce the spread of infections in a disaster because the responders will not have to continue touching common items such as clipboards and pens.

Potential Areas of Application: • Precision medicine • Drug discovery • Agriculture and crop development Patent Status: Under evaluation Inventor: Jianlin Cheng Contact: Brett Maland, or 573-882-1046

Anterior cruciate ligament (ACL) knee injuries occur four to six times more often in females than males. ACL rupture leads to costs between $17,000 to $25,000 for surgery and rehabilitation per patient, and nine to 12 months of missed participation in sports. An estimated 38,000 ACL injuries in girls and women in 2001 cost roughly $650 to $950 million to treat. There are several recognized biomechanical and neuro-muscular abnormalities that have been shown to increase the risk of ACL rupture in females, compared to males. If identified early through appropriate screening tests, aberrant jumping and landing patterns can be corrected with specific ACL injury prevention programs, leading to a relative risk reduction of 30 to 80 percent. These biomechanical and neuromuscular abnormalities are a modifiable risk factor, correctable by focused strengthening programs and neuromuscular re-education.


This invention consists of a system that allows multiple users in a mass-casualty disaster field triage scenario to communicate with each other and a central incident com-

Potential Area of Application: • Triaging mass-casualty emergencies Patent Status: Patent pending Inventors: Salman Ahmad, John Gillis, Calyam Prasad and Mihail Popescu Contact: Brett Maland, or 573-882-1046



The gold standard of measurement of these highrisk knee angles during a landing and jumping task uses multiple high speed cameras that track reflective markers placed on a test subject. A standard system is laboratory based and costs over $100,000 to install. MU researchers have a portable, inexpensive system (<$300) that can measure individuals much more quickly and efficiently than previous technology. This provides the opportunity for an instantaneous ACL injury risk assessment profile for the subject. Potential venues for ACL injury screening include orthopedic clinics, physical therapy units, public and private gyms and during school pre-participation annual physical examinations. This technology also can be used to create software and video games that use this device for immediate biofeedback to teach proper movement and exercise techniques. Potential Areas of Application: • Immediate biofeedback for improving neuromuscular control • Identify female athletes at high risk for ACL injury Intellectual Property Status: Copyright Inventors: Aaron Gray and Marge Skubic Contact: Brett Maland, or 573-882-1046


The present invention comprises software designed to teach objective assessment and training of medical diagnostic skills by simulating real-life scenarios more accurately than any other training system. The invention is an interactive software designed for pathology, which features visual-based, problem-based and incentivebased learning. It includes a database of imaged pathology slides and poses problems to users in the form of interactive case studies, wherein the user, after visualizing a picture, must determine the appropriate diagnosis/ clinical test/course of action from a set of given choices. Users then receive a monetary reward or punishment to simulate real-life, cost-based medical decision-making. Potential Area of Application: • Objective assessment and training of medical diagnostic skills relatedto pathology Patent Status: Under evaluation Inventors: Dmitriy Shin, Richard Hammer and Donald Doll Contact: Brett Maland, or 573-882-1046

QUALITY IMPROVEMENT PROJECT TRACKER This software is a robust tracking tool based on a new program design that features quality strategy, performance, and systems tracking using the interconnectivity of smartphones and the Internet. The software features accessible project count reports, project charter printouts and financial impact reports. Potential Areas of Application:


• Construction projects • Research projects Intellectual Property Status: Copyright Inventors: Koby Clements, Eric Franks, Douglas Wakefield and Kimberli Davis Contact: Brett Maland, or 573-882-1046


Flux Tensor With Split Gaussian models (FTSG) is a moving-object detection system with applications in security and in driverless vehicles. This hybrid system can handle challenges such as shadows, illumination changes, dynamic background, stopped and removed objects. FTSG is superior to other moving-object detection methods in handling certain classes of complex background dynamics like water fountains, rippling waves, thermal turbulence and weather conditions such as rain and snow. In other words, FTSG can detect moving objects even with noise that distorts other moving object detection systems. FTSG demonstrates superior performance in low-frame rate videos; nighttime shots; and pan, tilt and zoom (PTZ) camera videos. Potential Areas of Application: • Object detection • Security cameras Patent Status: Patent issued Inventors: Filiz Ersoy, Rui Wang and Kannappan Palaniappan Contact: Brett Maland, or 573-882-1046


MU researchers have created a fast and efficient bundle adjustment pipeline developed for refinement of camera parameters for aerial imagery, such as wide-area motion imagery and photogrammetry. The unique feature of this invention is that it contains a robust function capable of taking the sequentially acquired images and extracting features that are matched only between each two successive frames, while at the same time tracking the corresponding features that are constructed over multiple frames. This can be used for tracking objects as they move through frames and is extremely beneficial for high-pursuit scenarios where traditional technology would have trouble tracking objects as the helicopter moves and the light changes. Potential Areas of Application: • Military surveillance • Police surveillance • UAV photography • Movie industry Patent Status: Patent pending Inventors: Hadi Ali Akbarpour and Kannappan Palaniappan Contact: Brett Maland, or 573-882-1046

In traditional Chinese medicine, the tongue is an important indicator of overall health. Various areas of the tongue are thought to be associated with bodily functions. Traditional Chinese healers make health recommendations based on viewing the tongue. According to traditional Chinese medicine, different features of the tongue can indicate the health of internal organs such as the kidneys, bladder, intestine, spleen, stomach, liver, gallbladder, lungs and the heart. MU has developed a computational method that can standardize diagnoses based on the tongue. It is packaged with a database of tongue-health associations into a mobile app that will allow users to have traditional Chinese healing advice at their fingertips. Users can take a picture of their tongue, and the code developed at MU will compare that image with a large database of images to indicate the user’s organ health. Users also can monitor changes in their tongue using this mobile app to obtain even more personalized health information. Potential Area of Application: • Analysis of tongue to detect physical status via mobile device Intellectual Property Status: Copyright Inventors: Ye Duan, Dong Xu and Shao Li Contact: Brett Maland, or 573-882-1046


Our TREND software conveniently finds the main trends of change between measurements. This avoids timeconsuming standard interpretation of complicated data. TREND is suited for interpreting data collected by many kinds of laboratory techniques of imaging, spectroscopy and other analytical techniques. Many potential applications await in imaging modalities in medicine, laboratory imaging and environmental imaging. These applications include reconstructing the images from selected components, providing insight and simplification. In drug discovery, how tightly molecular “hits” bind to drug targets can be quantified faster than before. The time courses of physiological and chemical changes can be determined faster than before. TREND accomplishes all of this using a convenient implementation of the widely trusted technique of principal component analysis. R&D personnel will find TREND provides insight faster and easier.




Across a wide range of industries, from construction to pharmaceuticals, optimizing resource management, supply chain design, and logistics is essential to keep costs low and projects on time. UMSL researchers have developed a novel Resource Distribution Decision Tool for construction projects to significantly improve efficiencies. Current project management software does not account for exogenous disturbances, but this model takes this into consideration to determine the maximum rateof-return (ROR) and optimal project makespan. Compared to the traditional Critical Path Method, this new solution improved the ROR by 16 percent and shortens project makespan from 65 days to 59 days. Construction is one example of many industries that must deal with complex project schedules needing optimal allocation of resources in real time to save time and money. Current solutions on the market lack a dynamic optimization decision support function, which can have a huge impact on finish times and rate-of-return. The new Resource Distribution Tool provides this function. Potential Areas of Application: • Construction • Pharmaceutical • Oil & gas • Military applications • Supply chain • Logistics Intellectual Property Status: Copyright Inventors: Haitao Li and Ceki Halmen Contact: Craig Weilbaecher, or 314-516-4248

Potential Areas of Application: • Medical imaging and research imaging: easily identify key trends (e.g., time-dependent) and group similar images • Drug discovery: quantify affinities quickly and conveniently • Chemical reactions: quantify time courses easily Intellectual Property Status: Copyright Inventors: Steven Van Doren and Jia Xu Contact: Brett Maland, or 573-882-1046 57





A Reason to Smile

University of Missouri scientists are putting money where your mouth is. As anyone who’s had a loose filling can attest, it’s a pain in the mouth – and in the wallet. Hao Li and Qingsong Yu have developed a revolutionary new plasma brush for dentists, which would replace drilling with a less invasive approach using chemical reactions to prepare cavities for filling. The brush kills bacteria and forms a better bond between the tooth and the filling – making the need for a future replacement less likely. “One hundred-forty million tooth restorations cost Americans an estimated $50 billion a year, and it is estimated that replacement fillings constitute 75 percent of a dentist’s work,” says Li. “The plasma brush would help reduce those costs.” The plasma brush is just one innovation the scientists have developed through MU and their biomedical device

firm Nanova, Inc. Formed with the assistance of MU’s Missouri Small Business & Technology Development Centers, Nanova uses tiny strands called nanofibers – 1,000 times smaller than a human hair but stronger than stainless steel – to create bioabsorbable bone screws as well as an FDA-approved filling composite that is stronger and longer-lasting than current composites. Their work has captured global notice, with international venture capitalists investing more than $7 million in Nanova to produce dental products based on the nanomaterial technology. Drs. Hao Li and Qingsong Yu are faculty of Mechanical and Aerospace Engineering in the University of Missouri’s College of Engineering.

Missouri Small Business & Technology Development Center t e l

500 EAST WALNUT, SUITE 103, COLUMBIA, MO 65201 573-884-8087 • fax 573-884-7110 • WWW.COLUMBIASBDC.ORG

A partnership of MU Extension and the MU College of Engineering The Missouri Small Business and Technology Development Centers assist entrepreneurs with pre-venture, start-up or existing business issues including financial management, marketing, technology, product development and commercialization. The program’s objectives are to: • Provide entrepreneurial technical assistance to businesses and researchers • Help entrepreneurs create companies, jobs, investments and profits • Help researchers and technology entrepreneurs attract research dollars, including Small Business Innovation Research and Small Business Technology Transfer awards. • Assist businesses in winning government contracts. • Provide technology and economic value to businesses in Missouri via university faculty by facilitating knowledge transfer between faculty and businesses. Education and Training: The MO SBTDC and MO PTAC programs offer a variety of training and educational programs on a wide range of business topics. Each office is equipped to present programs that meet specific needs within its community.

STATE WIDE IMPAC T 2013-2015 Sales increases totaling $439 million Investments totaling $419 million 24,180 jobs created or retained Procurement awards totaling $1.4 billion

Funded in part through a cooperative agreement with the U.S. Small Business Administration. All opinions, conclusions or recommendations expressed are those of the author(s) and do not necessarily reflect the views of the SBA. Programs are extended to the public on a non-discriminatory basis. Reasonable accommodations for persons with disabilities will be made if requested at least two weeks in advance.

Committed to building a stronger entrepreneurial community

The Innovation Hub provides a place for innovators to work and collaborate with other creative minds

Secure office access 24/7/365 Unlimited secure internet access Official mailing address for your business Meeting rooms and two-way video conferencing available One-on-one business counseling Small business development classes Access to mentors

Join us for 1 Million Cups Eve r y We d n e s d ay @ 9am

500 East Walnut Street COLUMBIA, MISSOURI 573.442.8303 â&#x20AC;˘


Missouri TECH EXPO 2016 1601 S. Providence Rd., Suite 124, Columbia, MO 65211 573-882-6013 I I

University of Missouri Tech Catalog, FY2016  

Learn about technologies and innovations available for licensing from the four University of Missouri System campuses. Published in conjunct...

University of Missouri Tech Catalog, FY2016  

Learn about technologies and innovations available for licensing from the four University of Missouri System campuses. Published in conjunct...